1
|
Cummings J, Zhou Y, Lee G, Zhong K, Fonseca J, Cheng F. Alzheimer's disease drug development pipeline: 2024. Alzheimers Dement (N Y) 2024; 10:e12465. [PMID: 38659717 PMCID: PMC11040692 DOI: 10.1002/trc2.12465] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 02/27/2024] [Accepted: 02/29/2024] [Indexed: 04/26/2024]
Abstract
INTRODUCTION New therapies to prevent or delay the onset of symptoms, slow progression, or improve cognitive and behavioral symptoms of Alzheimer's disease (AD) are needed. METHODS We interrogated clinicaltrials.gov including all clinical trials assessing pharmaceutical therapies for AD active in on January 1, 2024. We used the Common Alzheimer's Disease Research Ontology (CADRO) to classify the targets of therapies in the pipeline. RESULTS There are 164 trials assessing 127 drugs across the 2024 AD pipeline. There were 48 trials in Phase 3 testing 32 drugs, 90 trials in Phase 2 assessing 81 drugs, and 26 trials in Phase 1 testing 25 agents. Of the 164 trials, 34% (N = 56) assess disease-modifying biological agents, 41% (N = 68) test disease-modifying small molecule drugs, 10% (N = 17) evaluate cognitive enhancing agents, and 14% (N = 23) test drugs for the treatment of neuropsychiatric symptoms. DISCUSSION Compared to the 2023 pipeline, there are fewer trials (164 vs. 187), fewer drugs (127 vs. 141), fewer new chemical entities (88 vs. 101), and a similar number of repurposed agents (39 vs. 40). Highlights In the 2024 Alzheimer's disease drug development pipeline, there are 164 clinical trials assessing 127 drugs.The 2024 Alzheimer's disease drug development pipeline has contracted compared to the 2023 Alzheimer pipeline with fewer trials, fewer drugs, and fewer new chemical entities.Drugs in the Alzheimer's disease drug development pipeline target a wide array of targets; the most common processes targeted include neurotransmitter receptors, inflammation, amyloid, and synaptic plasticity.The total development time for a potential Alzheimer's disease therapy to progress from nonclinical studies to FDA review is approximately 13 years.
Collapse
Affiliation(s)
- Jeffrey Cummings
- Chambers‐Grundy Center for Transformative NeuroscienceDepartment of Brain HealthSchool of Integrated Health SciencesUniversity of Nevada, Las Vegas (UNLV)Las VegasNevadaUSA
| | - Yadi Zhou
- Genomic Medicine InstituteLerner Research Institute, Cleveland ClinicClevelandOhioUSA
| | - Garam Lee
- Chambers‐Grundy Center for Transformative NeuroscienceDepartment of Brain HealthSchool of Integrated Health SciencesUniversity of Nevada, Las Vegas (UNLV)Las VegasNevadaUSA
| | - Kate Zhong
- Chambers‐Grundy Center for Transformative NeuroscienceDepartment of Brain HealthSchool of Integrated Health SciencesUniversity of Nevada, Las Vegas (UNLV)Las VegasNevadaUSA
| | - Jorge Fonseca
- Howard R Hughes College of EngineeringDepartment of Computer ScienceUniversity of Nevada, Las Vegas (UNLV)Las VegasNevadaUSA
| | - Feixiong Cheng
- Genomic Medicine InstituteLerner Research Institute, Cleveland ClinicClevelandOhioUSA
- Department of Molecular MedicineCleveland Clinic Lerner College of MedicineCase Western Reserve UniversityClevelandOhioUSA
- Case Comprehensive Cancer CenterCase Western Reserve University School of MedicineClevelandOhioUSA
- Cleveland Clinic Genome CenterLerner Research Institute, Cleveland ClinicClevelandOhioUSA
| |
Collapse
|
2
|
Sayyid ZN, Wang H, Cai Y, Gross AL, Swenor BK, Deal JA, Lin FR, Wanigatunga AA, Dougherty RJ, Tian Q, Simonsick EM, Ferrucci L, Schrack JA, Resnick SM, Agrawal Y. Sensory and motor deficits as contributors to early cognitive impairment. Alzheimers Dement 2024; 20:2653-2661. [PMID: 38375574 PMCID: PMC11032563 DOI: 10.1002/alz.13715] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/17/2023] [Revised: 01/03/2024] [Accepted: 01/04/2024] [Indexed: 02/21/2024]
Abstract
INTRODUCTION Age-related sensory and motor impairment are associated with risk of dementia. No study has examined the joint associations of multiple sensory and motor measures on prevalence of early cognitive impairment (ECI). METHODS Six hundred fifty participants in the Baltimore Longitudinal Study of Aging completed sensory and motor function tests. The association between sensory and motor function and ECI was examined using structural equation modeling with three latent factors corresponding to multisensory, fine motor, and gross motor function. RESULTS The multisensory, fine, and gross motor factors were all correlated (r = 0.74 to 0.81). The odds of ECI were lower for each additional unit improvement in the multisensory (32%), fine motor (30%), and gross motor factors (12%). DISCUSSION The relationship between sensory and motor impairment and emerging cognitive impairment may guide future intervention studies aimed at preventing and/or treating ECI. HIGHLIGHTS Sensorimotor function and early cognitive impairment (ECI) prevalence were assessed via structural equation modeling. The degree of fine and gross motor function is associated with indicators of ECI. The degree of multisensory impairment is also associated with indicators of ECI.
Collapse
Affiliation(s)
- Zahra N. Sayyid
- Department of Otolaryngology‐Head and Neck SurgeryJohns Hopkins School of MedicineBaltimoreMarylandUSA
| | - Hang Wang
- Department of EpidemiologyJohns Hopkins Bloomberg School of Public HealthBaltimoreMarylandUSA
- Center on Aging and HealthJohns Hopkins School of MedicineBaltimoreMarylandUSA
| | - Yurun Cai
- Department of Health and Community SystemsUniversity of Pittsburgh School of NursingPittsburghPennsylvaniaUSA
| | - Alden L. Gross
- Department of EpidemiologyJohns Hopkins Bloomberg School of Public HealthBaltimoreMarylandUSA
- Center on Aging and HealthJohns Hopkins School of MedicineBaltimoreMarylandUSA
| | - Bonnielin K. Swenor
- The Johns Hopkins School of NursingBaltimoreMarylandUSA
- The Johns Hopkins Disability Health Research Center, Johns Hopkins UniversityBaltimoreMarylandUSA
| | - Jennifer A. Deal
- Department of EpidemiologyJohns Hopkins Bloomberg School of Public HealthBaltimoreMarylandUSA
- Cochlear Center for Hearing and Public Health, Johns Hopkins Bloomberg School of Public HealthBaltimoreMarylandUSA
| | - Frank R. Lin
- Department of Otolaryngology‐Head and Neck SurgeryJohns Hopkins School of MedicineBaltimoreMarylandUSA
- Cochlear Center for Hearing and Public Health, Johns Hopkins Bloomberg School of Public HealthBaltimoreMarylandUSA
| | - Amal A. Wanigatunga
- Department of EpidemiologyJohns Hopkins Bloomberg School of Public HealthBaltimoreMarylandUSA
- Center on Aging and HealthJohns Hopkins School of MedicineBaltimoreMarylandUSA
| | - Ryan J. Dougherty
- Department of NeurologyJohns Hopkins School of MedicineBaltimoreMarylandUSA
| | - Qu Tian
- Intramural Research Program, National Institute on Aging, BaltimoreBaltimoreMarylandUSA
| | - Eleanor M. Simonsick
- Intramural Research Program, National Institute on Aging, BaltimoreBaltimoreMarylandUSA
| | - Luigi Ferrucci
- Intramural Research Program, National Institute on Aging, BaltimoreBaltimoreMarylandUSA
| | - Jennifer A. Schrack
- Department of EpidemiologyJohns Hopkins Bloomberg School of Public HealthBaltimoreMarylandUSA
- Center on Aging and HealthJohns Hopkins School of MedicineBaltimoreMarylandUSA
| | - Susan M. Resnick
- Intramural Research Program, National Institute on Aging, BaltimoreBaltimoreMarylandUSA
| | - Yuri Agrawal
- Department of Otolaryngology‐Head and Neck SurgeryJohns Hopkins School of MedicineBaltimoreMarylandUSA
| |
Collapse
|
3
|
Pillai JA, Bena J, Tousi B, Rothenberg K, Keene CD, Leverenz JB. Lewy body pathology modifies risk factors for cerebral amyloid angiopathy when comorbid with Alzheimer's disease pathology. Alzheimers Dement 2024; 20:2564-2574. [PMID: 38353367 PMCID: PMC11032524 DOI: 10.1002/alz.13704] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/04/2023] [Revised: 11/28/2023] [Accepted: 12/16/2023] [Indexed: 02/18/2024]
Abstract
INTRODUCTION Cerebral amyloid angiopathy (CAA) often accompanies dementia-associated pathologies and is important in the context of anti-amyloid monoclonal therapies and risk of hemorrhage. METHODS We conducted a retrospective neuropathology-confirmed study of 2384 participants in the National Alzheimer Coordinating Center cohort (Alzheimer's disease [AD], n = 1175; Lewy body pathology [LBP], n = 316; and mixed AD and LBP [AD-LBP], n = 893). We used logistic regression to evaluate age, sex, education, APOE ε4, neuritic plaques, and neurofibrillary tangles (NFTs) in CAA risk. RESULTS APOE ε4 increased CAA risk in all three groups, while younger age and higher NFT stages increased risk in AD and AD-LBP. In AD-LBP, male sex and lower education were additional risk factors. The odds of APOE ε4 carrier homozygosity related to CAA was higher in LBP (25.69) and AD-LBP (9.50) than AD (3.17). DISCUSSION AD and LBPs modify risk factors for CAA and should be considered in reviewing the risk of CAA. HIGHLIGHTS Lewy body pathology modifies risk factors for cerebral amyloid angiopathy (CAA) when present along with Alzheimer's disease (AD) neuropathology. In the context of anti-amyloid monoclonal therapies and their associated risks for hemorrhage, the risk of underlying CAA in mixed dementia with Lewy body pathology needs to be considered.
Collapse
Affiliation(s)
- Jagan A. Pillai
- Lou Ruvo Center for Brain HealthCleveland ClinicClevelandOhioUSA
- Neurological InstituteCleveland ClinicClevelandOhioUSA
- Department of NeurologyCleveland ClinicClevelandOhioUSA
| | - James Bena
- Quantitative Health SciencesCleveland ClinicClevelandOhioUSA
| | - Babak Tousi
- Lou Ruvo Center for Brain HealthCleveland ClinicClevelandOhioUSA
- Neurological InstituteCleveland ClinicClevelandOhioUSA
| | - Kasia Rothenberg
- Lou Ruvo Center for Brain HealthCleveland ClinicClevelandOhioUSA
- Neurological InstituteCleveland ClinicClevelandOhioUSA
| | - C. Dirk Keene
- Department of Laboratory Medicine and PathologyUniversity of Washington School of MedicineSeattleWashingtonUSA
| | - James B. Leverenz
- Lou Ruvo Center for Brain HealthCleveland ClinicClevelandOhioUSA
- Neurological InstituteCleveland ClinicClevelandOhioUSA
- Department of NeurologyCleveland ClinicClevelandOhioUSA
| |
Collapse
|
4
|
Maestre G, Hill C, Griffin P, Hall S, Hu W, Flatt J, Babulal G, Thorpe R, Henderson JN, Buchwald D, Manson S, Cicero E, Gilmore‐Bykovskyi A, Gamaldo A, Glover C, Barnes L, Kind A, James B, Zeki Al Hazzouri A, Wharton W, Caramelli P, Szanton S, Whitmer R, Benn Torres J, Deters K, Okonkwo O, Das R, Martinez‐Gonzalez K, Carrillo M. Promoting diverse perspectives: Addressing health disparities related to Alzheimer's and all dementias. Alzheimers Dement 2024; 20:3099-3107. [PMID: 38460119 PMCID: PMC11032522 DOI: 10.1002/alz.13752] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/10/2023] [Revised: 01/26/2024] [Accepted: 01/29/2024] [Indexed: 03/11/2024]
Abstract
Dementia research lacks appropriate representation of diverse groups who often face substantial adversity and greater risk of dementia. Current research participants are primarily well-resourced, non-Hispanic White, cisgender adults who live close to academic medical centers where much of the research is based. Consequently, the field faces a knowledge gap about Alzheimer's-related risk factors in those other groups. The Alzheimer's Association hosted a virtual conference on June 14-16, 2021, supported in part by the National Institute on Aging (R13 AG072859-01), focused on health disparities. The conference was held entirely online and consisted of 2 days of core programming and a day of focused meetings centered on American Indian and Alaska Natives and on LGBTQIA+ populations. Over 1300 registrants attended discussions focused on the structural and systemic inequities experienced across diverse groups, as well as ways to investigate and address these inequities.
Collapse
Affiliation(s)
- Gladys Maestre
- School of MedicineAlzheimer's Disease Resource Center for Minority Aging ResearchUniversity of Texas Rio Grande ValleyBrownsvilleTexasUSA
| | - Carl Hill
- Medical & Scientific RelationsAlzheimer's AssociationChicagoIllinoisUSA
| | - Percy Griffin
- Medical & Scientific RelationsAlzheimer's AssociationChicagoIllinoisUSA
| | - Stephen Hall
- Medical & Scientific RelationsAlzheimer's AssociationChicagoIllinoisUSA
| | - William Hu
- Rutgers Robert Wood Johnson Medical School and Rutgers Institute for HealthHealth Care Policy, and Aging ResearchNew BrunswickNew JerseyUSA
| | - Jason Flatt
- Department of Social and Behavioral HealthSchool of Public HealthUniversity of Nevada Las VegasLas VegasNevadaUSA
| | - Ganesh Babulal
- Department of NeurologySchool of MedicineWashington University in St. LouisSt. LouisMissouriUSA
| | - Roland Thorpe
- Center on AgingCenter on Health Disparities SolutionsHopkins Population CenterAlzheimer's Disease Resource Center for Minority Aging ResearchJohns Hopkins University Bloomberg School of Public HealthBaltimoreMarylandUSA
| | | | - Dedra Buchwald
- Institute for Research and Education to Advance Community Health Elson S Floyd College of Medicine Washington State UniversitySeattleWashingtonUSA
| | - Spero Manson
- Centers for American Indian and Alaska Native HealthUniversity of Colorado Anschutz Medical CampusAuroraColoradoUSA
| | - Ethan Cicero
- Nell Hodgson Woodruff School of NursingEmory UniversityAtlantaGeorgiaUSA
| | - Andrea Gilmore‐Bykovskyi
- BerbeeWalsh Department of Emergency MedicineUniversity of Wisconsin‐Madison School of Medicine and Public HealthMadisonWisconsinUSA
| | - Alyssa Gamaldo
- Pennsylvania State UniversityState CollegePennsylvaniaUSA
| | | | - Lisa Barnes
- Rush University Medical CenterChicagoIllinoisUSA
| | - Amy Kind
- BerbeeWalsh Department of Emergency MedicineUniversity of Wisconsin‐Madison School of Medicine and Public HealthMadisonWisconsinUSA
| | - Bryan James
- Rush University Medical CenterChicagoIllinoisUSA
| | - Adina Zeki Al Hazzouri
- Mailman School of Public HealthDepartment of EpidemiologyColumbia UniversityNew YorkNew YorkUSA
| | - Whitney Wharton
- Nell Hodgson Woodruff School of NursingEmory UniversityAtlantaGeorgiaUSA
| | - Paulo Caramelli
- Behavioral and Cognitive Neurology Unit, Faculdade de MedicinaUniversidade Federal de Minas GeraisBelo HorizonteBrazil
| | - Sarah Szanton
- Johns Hopkins University School of NursingBaltimoreMarylandUSA
| | - Rachel Whitmer
- Department of Public Health SciencesDepartment of NeurologyUniversity of California DavisDavisCaliforniaUSA
| | | | - Kacie Deters
- Department of NeurosciencesUniversity of California San Diego School of MedicineLa JollaCaliforniaUSA
| | - Ozioma Okonkwo
- Department of Medicine and the Wisconsin Alzheimer's Disease Research CenterUniversity of Wisconsin School of Medicine and Public HealthMadisonWisconsinUSA
| | - Rina Das
- National Institute on Minority Health and Health DisparitiesBethesdaMarylandUSA
| | | | - Maria Carrillo
- Medical & Scientific RelationsAlzheimer's AssociationChicagoIllinoisUSA
| |
Collapse
|
5
|
Jack CR, Wiste HJ, Algeciras‐Schimnich A, Weigand SD, Figdore DJ, Lowe VJ, Vemuri P, Graff‐Radford J, Ramanan VK, Knopman DS, Mielke MM, Machulda MM, Fields J, Schwarz CG, Cogswell PM, Senjem ML, Therneau TM, Petersen RC. Comparison of plasma biomarkers and amyloid PET for predicting memory decline in cognitively unimpaired individuals. Alzheimers Dement 2024; 20:2143-2154. [PMID: 38265198 PMCID: PMC10984437 DOI: 10.1002/alz.13651] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2023] [Revised: 11/22/2023] [Accepted: 11/27/2023] [Indexed: 01/25/2024]
Abstract
BACKGROUND We compared the ability of several plasma biomarkers versus amyloid positron emission tomography (PET) to predict rates of memory decline among cognitively unimpaired individuals. METHODS We studied 645 Mayo Clinic Study of Aging participants. Predictor variables were age, sex, education, apolipoprotein E (APOE) ε4 genotype, amyloid PET, and plasma amyloid beta (Aβ)42/40, phosphorylated tau (p-tau)181, neurofilament light (NfL), glial fibrillary acidic protein (GFAP), and p-tau217. The outcome was a change in a memory composite measure. RESULTS All plasma biomarkers, except NfL, were associated with mean memory decline in models with individual biomarkers. However, amyloid PET and plasma p-tau217, along with age, were key variables independently associated with mean memory decline in models combining all predictors. Confidence intervals were narrow for estimates of population mean prediction, but person-level prediction intervals were wide. DISCUSSION Plasma p-tau217 and amyloid PET provide useful information about predicting rates of future cognitive decline in cognitively unimpaired individuals at the population mean level, but not at the individual person level.
Collapse
Affiliation(s)
| | - Heather J. Wiste
- Department of Quantitative Health SciencesMayo ClinicRochesterMinnesotaUSA
| | | | - Stephen D. Weigand
- Department of Quantitative Health SciencesMayo ClinicRochesterMinnesotaUSA
| | - Dan J. Figdore
- Department of Laboratory MedicineMayo ClinicRochesterMinnesotaUSA
| | - Val J. Lowe
- Department of Nuclear MedicineMayo ClinicRochesterMinnesotaUSA
| | | | | | | | | | - Michelle M. Mielke
- Department of Epidemiology and PreventionWake Forest University School of MedicineWinston‐SalemNorth CarolinaUSA
| | - Mary M. Machulda
- Department of Psychiatry and PsychologyMayo ClinicRochesterMinnesotaUSA
| | - Julie Fields
- Department of Psychiatry and PsychologyMayo ClinicRochesterMinnesotaUSA
| | | | | | | | - Terry M. Therneau
- Department of Quantitative Health SciencesMayo ClinicRochesterMinnesotaUSA
| | | |
Collapse
|
6
|
Chumin EJ, Burton CP, Silvola R, Miner EW, Persohn SC, Veronese M, Territo PR. Brain metabolic network covariance and aging in a mouse model of Alzheimer's disease. Alzheimers Dement 2024; 20:1538-1549. [PMID: 38032015 PMCID: PMC10984484 DOI: 10.1002/alz.13538] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2023] [Revised: 10/09/2023] [Accepted: 10/11/2023] [Indexed: 12/01/2023]
Abstract
INTRODUCTION Alzheimer's disease (AD), the leading cause of dementia worldwide, represents a human and financial impact for which few effective drugs exist to treat the disease. Advances in molecular imaging have enabled assessment of cerebral glycolytic metabolism, and network modeling of brain region have linked to alterations in metabolic activity to AD stage. METHODS We performed 18 F-FDG positron emission tomography (PET) imaging in 4-, 6-, and 12-month-old 5XFAD and littermate controls (WT) of both sexes and analyzed region data via brain metabolic covariance analysis. RESULTS The 5XFAD model mice showed age-related changes in glucose uptake relative to WT mice. Analysis of community structure of covariance networks was different across age and sex, with a disruption of metabolic coupling in the 5XFAD model. DISCUSSION The current study replicates clinical AD findings and indicates that metabolic network covariance modeling provides a translational tool to assess disease progression in AD models.
Collapse
Affiliation(s)
- Evgeny J. Chumin
- Stark Neurosciences Research InstituteIndiana University School of MedicineIndianapolisIndianaUSA
- Department of Psychological and Brain SciencesIndiana UniversityBloomingtonIndianaUSA
- Indiana University Network Science Institute, Indiana UniversityBloomingtonIndianaUSA
| | - Charles P. Burton
- Stark Neurosciences Research InstituteIndiana University School of MedicineIndianapolisIndianaUSA
| | - Rebecca Silvola
- Department of MedicineDivision of Clinical PharmacologyIndiana University School of MedicineIndianapolisIndianaUSA
- Eli Lilly and CompanyIndianapolisIndianaUSA
| | - Ethan W. Miner
- Stark Neurosciences Research InstituteIndiana University School of MedicineIndianapolisIndianaUSA
| | - Scott C. Persohn
- Stark Neurosciences Research InstituteIndiana University School of MedicineIndianapolisIndianaUSA
| | - Mattia Veronese
- Department of Information EngineeringUniversity of PaduaPaduaItaly
- Department of NeuroimagingKing's College LondonLondonUK
| | - Paul R. Territo
- Stark Neurosciences Research InstituteIndiana University School of MedicineIndianapolisIndianaUSA
- Department of MedicineDivision of Clinical PharmacologyIndiana University School of MedicineIndianapolisIndianaUSA
| |
Collapse
|
7
|
Walker JM, Orr ME, Orr TC, Thorn EL, Christie TD, Yokoda RT, Vij M, Ehrenberg AJ, Marx GA, McKenzie AT, Kauffman J, Selmanovic E, Wisniewski T, Drummond E, White CL, Crary JF, Farrell K, Kautz TF, Daoud EV, Richardson TE. Spatial proteomics of hippocampal subfield-specific pathology in Alzheimer's disease and primary age-related tauopathy. Alzheimers Dement 2024; 20:783-797. [PMID: 37777848 PMCID: PMC10916977 DOI: 10.1002/alz.13484] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/06/2023] [Revised: 08/25/2023] [Accepted: 08/29/2023] [Indexed: 10/02/2023]
Abstract
INTRODUCTION Alzheimer's disease (AD) and primary age-related tauopathy (PART) both harbor 3R/4R hyperphosphorylated-tau (p-tau)-positive neurofibrillary tangles (NFTs) but differ in the spatial p-tau development in the hippocampus. METHODS Using Nanostring GeoMx Digital Spatial Profiling, we compared protein expression within hippocampal subregions in NFT-bearing and non-NFT-bearing neurons in AD (n = 7) and PART (n = 7) subjects. RESULTS Proteomic measures of synaptic health were inversely correlated with the subregional p-tau burden in AD and PART, and there were numerous differences in proteins involved in proteostasis, amyloid beta (Aβ) processing, inflammation, microglia, oxidative stress, and neuronal/synaptic health between AD and PART and between definite PART and possible PART. DISCUSSION These results suggest subfield-specific proteome differences that may explain some of the differences in Aβ and p-tau distribution and apparent pathogenicity. In addition, hippocampal neurons in possible PART may have more in common with AD than with definite PART, highlighting the importance of Aβ in the pathologic process. HIGHLIGHTS Synaptic health is inversely correlated with local p-tau burden. The proteome of NFT- and non-NFT-bearing neurons is influenced by the presence of Aβ in the hippocampus. Neurons in possible PART cases share more proteomic similarities with neurons in ADNC than they do with neurons in definite PART cases.
Collapse
|
8
|
Abdolahi F, Yu V, Varma R, Zhou X, Wang RK, D'Orazio LM, Zhao C, Jann K, Wang DJ, Kashani AH, Jiang X. Retinal perfusion is linked to cognition and brain MRI biomarkers in Black Americans. Alzheimers Dement 2024; 20:858-868. [PMID: 37800578 PMCID: PMC10917050 DOI: 10.1002/alz.13469] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/15/2023] [Revised: 08/14/2023] [Accepted: 08/17/2023] [Indexed: 10/07/2023]
Abstract
INTRODUCTION We investigated whether retinal capillary perfusion is a biomarker of cerebral small vessel disease and impaired cognition among Black Americans, an understudied group at higher risk for dementia. METHODS We enrolled 96 Black Americans without known cognitive impairment. Four retinal perfusion measures were derived using optical coherence tomography angiography. Neurocognitive assessment and brain magnetic resonance imaging (MRI) were performed. Multiple linear regression analyses were performed. RESULTS Lower retinal capillary perfusion was correlated with worse Oral Symbol Digit Test (P < = 0.005) and Fluid Cognition Composite scores (P < = 0.02), but not with the Crystallized Cognition Composite score (P > = 0.41). Lower retinal perfusion was also correlated with higher free water and peak width of skeletonized mean diffusivity, and lower fractional anisotropy (all P < 0.05) on MRI (N = 35). DISCUSSION Lower retinal capillary perfusion is associated with worse information processing, fluid cognition, and MRI biomarkers of cerebral small vessel disease, but is not related to crystallized cognition.
Collapse
Affiliation(s)
- Farzan Abdolahi
- Department of OphthalmologyUniversity of Southern California Keck School of MedicineLos AngelesCaliforniaUSA
| | - Victoria Yu
- Department of OphthalmologyUniversity of Southern California Keck School of MedicineLos AngelesCaliforniaUSA
| | - Rohit Varma
- Southern California Eye InstituteCHA Hollywood Presbyterian Medical CenterLos AngelesCaliforniaUSA
| | - Xiao Zhou
- Department of BioengineeringUniversity of WashingtonSeattleWashingtonUSA
| | - Ruikang K. Wang
- Department of BioengineeringUniversity of WashingtonSeattleWashingtonUSA
- Department of OphthalmologyUniversity of WashingtonSeattleWashingtonUSA
| | - Lina M. D'Orazio
- Department of NeurologyUniversity of Southern California Keck School of MedicineLos AngelesCaliforniaUSA
| | - Chenyang Zhao
- Laboratory of FMRI TechnologyStevens Neuroimaging and Informatics InstituteUniversity of Southern California Keck School of MedicineLos AngelesCaliforniaUSA
| | - Kay Jann
- Laboratory of FMRI TechnologyStevens Neuroimaging and Informatics InstituteUniversity of Southern California Keck School of MedicineLos AngelesCaliforniaUSA
| | - Danny J. Wang
- Department of NeurologyUniversity of Southern California Keck School of MedicineLos AngelesCaliforniaUSA
- Laboratory of FMRI TechnologyStevens Neuroimaging and Informatics InstituteUniversity of Southern California Keck School of MedicineLos AngelesCaliforniaUSA
| | - Amir H. Kashani
- Department of OphthalmologyWilmer Eye InstituteJohns Hopkins University School of MedicineBaltimoreMarylandUSA
| | - Xuejuan Jiang
- Department of OphthalmologyUniversity of Southern California Keck School of MedicineLos AngelesCaliforniaUSA
| |
Collapse
|
9
|
Tang H, Guo J, Shaaban CE, Feng Z, Wu Y, Magoc T, Hu X, Donahoo WT, DeKosky ST, Bian J. Heterogeneous treatment effects of metformin on risk of dementia in patients with type 2 diabetes: A longitudinal observational study. Alzheimers Dement 2024; 20:975-985. [PMID: 37830443 PMCID: PMC10917005 DOI: 10.1002/alz.13480] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2023] [Revised: 08/14/2023] [Accepted: 08/20/2023] [Indexed: 10/14/2023]
Abstract
INTRODUCTION Little is known about the heterogeneous treatment effects of metformin on dementia risk in people with type 2 diabetes (T2D). METHODS Participants (≥ 50 years) with T2D and normal cognition at baseline were identified from the National Alzheimer's Coordinating Center database (2005-2021). We applied a doubly robust learning approach to estimate risk differences (RD) with a 95% confidence interval (CI) for dementia risk between metformin use and no use in the overall population and subgroups identified through a decision tree model. RESULTS Among 1393 participants, 104 developed dementia over a 4-year median follow-up. Metformin was significantly associated with a lower risk of dementia in the overall population (RD, -3.2%; 95% CI, -6.2% to -0.2%). We identified four subgroups with varied risks for dementia, defined by neuropsychiatric disorders, non-steroidal anti-inflammatory drugs, and antidepressant use. DISCUSSION Metformin use was significantly associated with a lower risk of dementia in individuals with T2D, with significant variability among subgroups.
Collapse
Affiliation(s)
- Huilin Tang
- Department of Pharmaceutical Outcomes and PolicyUniversity of Florida College of PharmacyGainesvilleFloridaUSA
| | - Jingchuan Guo
- Department of Pharmaceutical Outcomes and PolicyUniversity of Florida College of PharmacyGainesvilleFloridaUSA
- Center for Drug Evaluation and SafetyUniversity of FloridaGainesvilleFloridaUSA
| | - C. Elizabeth Shaaban
- Department of EpidemiologySchool of Public HealthUniversity of PittsburghPittsburghPennsylvaniaUSA
- Alzheimer's Disease Research CenterUniversity of PittsburghPittsburghPennsylvaniaUSA
| | - Zheng Feng
- Department of Health Outcomes and Biomedical InformaticsCollege of MedicineUniversity of FloridaGainesvilleFloridaUSA
| | - Yonghui Wu
- Department of Health Outcomes and Biomedical InformaticsCollege of MedicineUniversity of FloridaGainesvilleFloridaUSA
| | - Tanja Magoc
- Clinical and Translational Science InstituteUniversity of FloridaGainesvilleFloridaUSA
| | - Xia Hu
- DATA LabDepartment of Computer ScienceRice UniversityHoustonTexasUSA
| | - William T Donahoo
- Department of MedicineCollege of MedicineUniversity of FloridaGainesvilleFloridaUSA
| | - Steven T. DeKosky
- Department of Neurology and McKnight Brain InstituteCollege of MedicineUniversity of FloridaGainesvilleFloridaUSA
- Florida Alzheimer's Disease Research Center (ADRC)University of FloridaGainesvilleFloridaUSA
| | - Jiang Bian
- Department of Health Outcomes and Biomedical InformaticsCollege of MedicineUniversity of FloridaGainesvilleFloridaUSA
| |
Collapse
|
10
|
Zheng A, Hoff KA, Hanna A, Einarsdóttir S, Rounds J, Briley DA. Job characteristics and personality change in young adulthood: A 12-year longitudinal study and replication. J Pers 2024; 92:298-315. [PMID: 37072929 PMCID: PMC10949344 DOI: 10.1111/jopy.12836] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2022] [Revised: 01/03/2023] [Accepted: 03/23/2023] [Indexed: 04/20/2023]
Abstract
OBJECTIVE Personality changes are related to successfully performing adult occupational roles which require teamwork, duty, and managing stress. However, it is unclear how personality development relates to specific job characteristics that vary across occupations. METHOD We investigated whether 151 objective job characteristics, derived from the Occupational Information Network (O*NET), were associated with personality levels and changes in a 12-year longitudinal sample followed over the school to work transition. Using cross-validated regularized modeling, we combined two Icelandic longitudinal datasets (total N = 1054) and constructed an individual-level, aggregated job characteristics score that maximized prediction of personality levels at baseline and change over time. RESULTS The strongest association was found for level of openness (0.25), followed by conscientiousness (0.16) and extraversion (0.14). Overall, aggregated job characteristics had a stronger prediction for personality intercepts (0.14) than slopes (0.10). These results were subsequently replicated in a U.S. sample using levels of the Big Five as the dependent variable. This indicates that associations between job characteristics and personality are generalizable across life stages and nations. CONCLUSIONS Our findings suggest that job titles are a valuable resource that can be linked to personality to better understand factors that influence psychological development. Further work is needed to document the prospective validity of job characteristics across a wider range of occupations and age.
Collapse
Affiliation(s)
- Anqing Zheng
- Department of PsychologyUniversity of California, RiversideRiversideCAUSA
| | - Kevin A. Hoff
- Department of PsychologyMichigan State UniversityEast LansingMIUSA
| | - Alexis Hanna
- Department of ManagementUniversity of Nevada, RenoRenoNVUSA
| | - Sif Einarsdóttir
- Department of Sociology, Anthropology and Ethnography and FolkloristicsUniversity of IcelandReykjavikIceland
| | - James Rounds
- Department of PsychologyUniversity of Illinois, Urbana‐ChampaignUrbanaILUSA
| | - D. A. Briley
- Department of PsychologyUniversity of Illinois, Urbana‐ChampaignUrbanaILUSA
| |
Collapse
|
11
|
Trombetta BA, Wu C, Kuo E, de Geus MB, Dodge HH, Carlyle BC, Kivisäkk P, Arnold SE. Cerebrospinal fluid biomarker profiling of diverse pathophysiological domains in Alzheimer's disease. Alzheimers Dement (N Y) 2024; 10:e12440. [PMID: 38356471 PMCID: PMC10865489 DOI: 10.1002/trc2.12440] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 07/07/2023] [Revised: 11/20/2023] [Accepted: 11/22/2023] [Indexed: 02/16/2024]
Abstract
INTRODUCTION While Alzheimer's disease (AD) is defined by amyloid-β plaques and tau tangles in the brain, it is evident that many other pathophysiological processes such as inflammation, neurovascular dysfunction, oxidative stress, and metabolic derangements also contribute to the disease process and that varying contributions of these pathways may reflect the heterogeneity of AD. Here, we used a previously validated panel of cerebrospinal fluid (CSF) biomarkers to explore the degree to which different pathophysiological domains are dysregulated in AD and how they relate to each other. METHODS Twenty-five CSF biomarkers were analyzed in individuals with a clinical diagnosis of AD verified by positive CSF AD biomarkers (AD, n = 54) and cognitively unimpaired controls negative for CSF AD biomarkers (CU-N, n = 26) using commercial single- and multi-plex immunoassays. RESULTS We noted that while AD was associated with increased levels of only three biomarkers (MMP-10, FABP3, and 8OHdG) on a group level, half of all AD participants had increased levels of biomarkers belonging to at least two pathophysiological domains reflecting the diversity in AD. LASSO modeling showed that a panel of FABP3, 24OHC, MMP-10, MMP-2, and 8OHdG constituted the most relevant and minimally correlated set of variables differentiating AD from CU-N. Interestingly, factor analysis showed that two markers of metabolism and oxidative stress (24OHC and 8OHdG) contributed independent information separate from MMP-10 and FABP3 suggestive of two independent pathophysiological pathways in AD, one reflecting neurodegeneration and vascular pathology, and the other associated with metabolism and oxidative stress. DISCUSSION Better understanding of the heterogeneity among individuals with AD and the different contributions of pathophysiological processes besides amyloid-β and tau will be crucial for optimizing personalized treatment strategies. Highlights A panel of 25 highly validated biomarker assays were measured in CSF.MMP10, FABP3, and 8OHdG were increased in AD in univariate analysis.Many individuals with AD had increased levels of more than one biomarker.Markers of metabolism and oxidative stress contributed to an AD multianalyte profile.Assessing multiple biomarker domains is important to understand disease heterogeneity.
Collapse
Affiliation(s)
- Bianca A. Trombetta
- Department of Neurology, Alzheimer's Clinical and Translational Research UnitMassachusetts General Hospital, Harvard Medical SchoolBostonMassachusettsUSA
| | - Chao‐Yi Wu
- Department of Neurology, Alzheimer's Clinical and Translational Research UnitMassachusetts General Hospital, Harvard Medical SchoolBostonMassachusettsUSA
| | - Evan Kuo
- Department of Neurology, Alzheimer's Clinical and Translational Research UnitMassachusetts General Hospital, Harvard Medical SchoolBostonMassachusettsUSA
| | - Matthijs B. de Geus
- Department of Neurology, Alzheimer's Clinical and Translational Research UnitMassachusetts General Hospital, Harvard Medical SchoolBostonMassachusettsUSA
- Department of Cell & Chemical BiologyLeiden University Medical CenterLeidenThe Netherlands
| | - Hiroko H. Dodge
- Department of Neurology, Alzheimer's Clinical and Translational Research UnitMassachusetts General Hospital, Harvard Medical SchoolBostonMassachusettsUSA
| | - Becky C. Carlyle
- Department of Neurology, Alzheimer's Clinical and Translational Research UnitMassachusetts General Hospital, Harvard Medical SchoolBostonMassachusettsUSA
- Department of Physiology, Anatomy and GeneticsUniversity of OxfordOxfordUK
- Kavli Institute for Nanoscience DiscoveryUniversity of OxfordOxfordUK
| | - Pia Kivisäkk
- Department of Neurology, Alzheimer's Clinical and Translational Research UnitMassachusetts General Hospital, Harvard Medical SchoolBostonMassachusettsUSA
| | - Steven E. Arnold
- Department of Neurology, Alzheimer's Clinical and Translational Research UnitMassachusetts General Hospital, Harvard Medical SchoolBostonMassachusettsUSA
| |
Collapse
|
12
|
Nikmaneshi MR, Baish JW, Zhou H, Padera TP, Munn LL. Transport Barriers Influence the Activation of Anti-Tumor Immunity: A Systems Biology Analysis. Adv Sci (Weinh) 2023; 10:e2304076. [PMID: 37949675 PMCID: PMC10754116 DOI: 10.1002/advs.202304076] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/20/2023] [Revised: 10/07/2023] [Indexed: 11/12/2023]
Abstract
Effective anti-cancer immune responses require activation of one or more naïve T cells. If the correct naïve T cell encounters its cognate antigen presented by an antigen presenting cell, then the T cell can activate and proliferate. Here, mathematical modeling is used to explore the possibility that immune activation in lymph nodes is a rate-limiting step in anti-cancer immunity and can affect response rates to immune checkpoint therapy. The model provides a mechanistic framework for optimizing cancer immunotherapy and developing testable solutions to unleash anti-tumor immune responses for more patients with cancer. The results show that antigen production rate and trafficking of naïve T cells into the lymph nodes are key parameters and that treatments designed to enhance tumor antigen production can improve immune checkpoint therapies. The model underscores the potential of radiation therapy in augmenting tumor immunogenicity and neoantigen production for improved ICB therapy, while emphasizing the need for careful consideration in cases where antigen levels are already sufficient to avoid compromising the immune response.
Collapse
Affiliation(s)
- Mohammad R. Nikmaneshi
- Department of Radiation OncologyMassachusetts General Hospital and Harvard Medical SchoolBostonMA02114USA
| | - James W. Baish
- Biomedical EngineeringBucknell UniversityLewisburgPA17837USA
| | - Hengbo Zhou
- Department of Radiation OncologyMassachusetts General Hospital and Harvard Medical SchoolBostonMA02114USA
| | - Timothy P. Padera
- Department of Radiation OncologyMassachusetts General Hospital and Harvard Medical SchoolBostonMA02114USA
| | - Lance L. Munn
- Department of Radiation OncologyMassachusetts General Hospital and Harvard Medical SchoolBostonMA02114USA
| |
Collapse
|
13
|
Erichsen J, Craft S. Targeting immunometabolic pathways for combination therapy in Alzheimer's disease. Alzheimers Dement (N Y) 2023; 9:e12423. [PMID: 37786483 PMCID: PMC10541802 DOI: 10.1002/trc2.12423] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 05/22/2023] [Revised: 08/25/2023] [Accepted: 08/26/2023] [Indexed: 10/04/2023]
Abstract
The recent success of disease-modifying anti-amyloid monoclonal antibodies in slowing Alzheimer's disease (AD) symptoms has been an exciting step forward for the field. Despite successfully clearing amyloid from the brain, however, only modest symptomatic improvement has been demonstrated, and treatment-related side effects such as amyloid-related imaging abnormalities (ARIA) limit use for some. These limitations suggest that fully efficacious AD treatment may require combination therapy regimens, as are used in other complex disorders such as cancer and HIV. One reasonable strategy may be to use agents that address the biological changes that predict future amyloid accumulation, or accompany amyloid accumulation in preclinical disease states. Immunometabolic pathways, including the insulin signaling pathway, are dysregulated at the earliest stages of AD, concomitant with amyloid accumulation. It is plausible that agents that target these pathways may work synergistically with anti-amyloid therapies to halt AD progression. Insulin signaling is integrally involved in innate and adaptive immune systems, with pleiotropic effects that moderate pro- and anti-inflammatory responses. Metabolic modulators that enhance insulin sensitivity and function, such as GLP-1 receptor agonists, SGLT2 inhibitors, and insulin itself have been shown to improve immune function and reduce chronic inflammation. Additional effects of insulin and metabolic modulators demonstrated in preclinical and clinical studies of AD include increased clearance of amyloid-β, slowed tau progression, improved vascular function and lipid metabolism, reduced synaptotoxicity, and improved cognitive and functional outcomes. A large number of compounds that treat metabolic disorders have been extensively characterized with respect to mechanism of action and safety, and thus are readily available to be repurposed for combination therapy protocols. Determining the most successful combination regimens of these agents together with disease-modifying therapies, and the appropriate timing of treatment, are promising next steps in the quest to treat and prevent AD.
Collapse
Affiliation(s)
- Jennifer Erichsen
- Department of Internal MedicineDivision of Gerontology and Geriatric MedicineWake Forest School of MedicineWinston‐SalemNorth CarolinaUSA
| | - Suzanne Craft
- Department of Internal MedicineDivision of Gerontology and Geriatric MedicineWake Forest School of MedicineWinston‐SalemNorth CarolinaUSA
| |
Collapse
|
14
|
Ally M, Sugarman MA, Zetterberg H, Blennow K, Ashton NJ, Karikari TK, Aparicio HJ, Frank B, Tripodis Y, Martin B, Palmisano JN, Steinberg EG, Simkin I, Farrer LA, Jun GR, Turk KW, Budson AE, O'Connor MK, Au R, Goldstein LE, Kowall NW, Killiany R, Stern RA, Stein TD, McKee AC, Qiu WQ, Mez J, Alosco ML. Cross-sectional and longitudinal evaluation of plasma glial fibrillary acidic protein to detect and predict clinical syndromes of Alzheimer's disease. Alzheimers Dement (Amst) 2023; 15:e12492. [PMID: 37885919 PMCID: PMC10599277 DOI: 10.1002/dad2.12492] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 04/19/2023] [Revised: 09/15/2023] [Accepted: 09/26/2023] [Indexed: 10/28/2023]
Abstract
Introduction This study examined plasma glial fibrillary acidic protein (GFAP) as a biomarker of cognitive impairment due to Alzheimer's disease (AD) with and against plasma neurofilament light chain (NfL), and phosphorylated tau (p-tau)181+231. Methods Plasma samples were analyzed using Simoa platform for 567 participants spanning the AD continuum. Cognitive diagnosis, neuropsychological testing, and dementia severity were examined for cross-sectional and longitudinal outcomes. Results Plasma GFAP discriminated AD dementia from normal cognition (adjusted mean difference = 0.90 standard deviation [SD]) and mild cognitive impairment (adjusted mean difference = 0.72 SD), and demonstrated superior discrimination compared to alternative plasma biomarkers. Higher GFAP was associated with worse dementia severity and worse performance on 11 of 12 neuropsychological tests. Longitudinally, GFAP predicted decline in memory, but did not predict conversion to mild cognitive impairment or dementia. Discussion Plasma GFAP was associated with clinical outcomes related to suspected AD and could be of assistance in a plasma biomarker panel to detect in vivo AD.
Collapse
Affiliation(s)
- Madeline Ally
- Boston University Alzheimer's Disease Research Center and CTE CenterBoston University Chobanian & Avedisian School of MedicineBostonMassachusettsUSA
- Department of PsychologyUniversity of ArizonaTucsonArizonaUSA
| | - Michael A. Sugarman
- Boston University Alzheimer's Disease Research Center and CTE CenterBoston University Chobanian & Avedisian School of MedicineBostonMassachusettsUSA
- Department of NeurologyMedical University of South CarolinaCharlestonSouth CarolinaUSA
| | - Henrik Zetterberg
- Department of Neurodegenerative DiseaseUCL Institute of NeurologyLondonUK
- UK Dementia Research Institute at UCL, UCL Institute of NeurologyUniversity College LondonLondonUK
- Clinical Neurochemistry LaboratorySahlgrenska University HospitalMölndalSweden
- Department of Psychiatry and Neurochemistry, Institute of Neuroscience and PhysiologyThe Sahlgrenska Academy at the University of GothenburgGothenburgSweden
| | - Kaj Blennow
- Clinical Neurochemistry LaboratorySahlgrenska University HospitalMölndalSweden
- Department of Psychiatry and Neurochemistry, Institute of Neuroscience and PhysiologyThe Sahlgrenska Academy at the University of GothenburgGothenburgSweden
| | - Nicholas J. Ashton
- Department of Psychiatry and Neurochemistry, Institute of Neuroscience and PhysiologyThe Sahlgrenska Academy at the University of GothenburgGothenburgSweden
- Maurice Wohl Clinical Neuroscience Institute, Institute of Psychiatry, Psychology, and NeuroscienceKing's College LondonLondonUK
- NIHR Biomedical Research Centre for Mental Health and Biomedical Research Unit for Dementia at South London and MaudsleyNHS FoundationLondonUK
- Centre for Age‐Related MedicineStavanger University HospitalStavangerNorway
| | - Thomas K. Karikari
- Clinical Neurochemistry LaboratorySahlgrenska University HospitalMölndalSweden
- Department of Psychiatry and Neurochemistry, Institute of Neuroscience and PhysiologyThe Sahlgrenska Academy at the University of GothenburgGothenburgSweden
- Department of PsychiatryUniversity of Pittsburgh School of MedicinePittsburghPennsylvaniaUSA
| | - Hugo J. Aparicio
- Boston University Alzheimer's Disease Research Center and CTE CenterBoston University Chobanian & Avedisian School of MedicineBostonMassachusettsUSA
- Department of NeurologyBoston University Chobanian & Avedisian School of MedicineBostonMassachusettsUSA
| | - Brandon Frank
- Boston University Alzheimer's Disease Research Center and CTE CenterBoston University Chobanian & Avedisian School of MedicineBostonMassachusettsUSA
- US Department of Veterans AffairsVA Boston Healthcare SystemJamaica PlainMassachusettsUSA
| | - Yorghos Tripodis
- Boston University Alzheimer's Disease Research Center and CTE CenterBoston University Chobanian & Avedisian School of MedicineBostonMassachusettsUSA
- Department of BiostatisticsBoston University School of Public HealthBostonMassachusettsUSA
| | - Brett Martin
- Boston University Alzheimer's Disease Research Center and CTE CenterBoston University Chobanian & Avedisian School of MedicineBostonMassachusettsUSA
- Biostatistics and Epidemiology Data Analytics CenterBoston University School of Public HealthBostonMassachusettsUSA
| | - Joseph N. Palmisano
- Boston University Alzheimer's Disease Research Center and CTE CenterBoston University Chobanian & Avedisian School of MedicineBostonMassachusettsUSA
- Biostatistics and Epidemiology Data Analytics CenterBoston University School of Public HealthBostonMassachusettsUSA
| | - Eric G. Steinberg
- Boston University Alzheimer's Disease Research Center and CTE CenterBoston University Chobanian & Avedisian School of MedicineBostonMassachusettsUSA
| | - Irene Simkin
- Department of MedicineBoston University Chobanian & Avedisian School of MedicineBostonMassachusettsUSA
| | - Lindsay A. Farrer
- Boston University Alzheimer's Disease Research Center and CTE CenterBoston University Chobanian & Avedisian School of MedicineBostonMassachusettsUSA
- Department of NeurologyBoston University Chobanian & Avedisian School of MedicineBostonMassachusettsUSA
- Department of BiostatisticsBoston University School of Public HealthBostonMassachusettsUSA
- Department of MedicineBoston University Chobanian & Avedisian School of MedicineBostonMassachusettsUSA
- The Framingham Heart StudyFraminghamMassachusettsUSA
- Department of EpidemiologyBoston University School of Public HealthBostonMassachusettsUSA
- Department of OphthalmologyBoston University Chobanian & Avedisian School of MedicineBostonMassachusettsUSA
| | - Gyungah R. Jun
- Department of MedicineBoston University Chobanian & Avedisian School of MedicineBostonMassachusettsUSA
| | - Katherine W. Turk
- Boston University Alzheimer's Disease Research Center and CTE CenterBoston University Chobanian & Avedisian School of MedicineBostonMassachusettsUSA
- Department of NeurologyBoston University Chobanian & Avedisian School of MedicineBostonMassachusettsUSA
- US Department of Veterans AffairsVA Boston Healthcare SystemJamaica PlainMassachusettsUSA
| | - Andrew E. Budson
- Boston University Alzheimer's Disease Research Center and CTE CenterBoston University Chobanian & Avedisian School of MedicineBostonMassachusettsUSA
- Department of NeurologyBoston University Chobanian & Avedisian School of MedicineBostonMassachusettsUSA
- US Department of Veterans AffairsVA Boston Healthcare SystemJamaica PlainMassachusettsUSA
| | - Maureen K. O'Connor
- Boston University Alzheimer's Disease Research Center and CTE CenterBoston University Chobanian & Avedisian School of MedicineBostonMassachusettsUSA
- Department of NeuropsychologyEdith Nourse Rogers Memorial Veterans HospitalBedfordMassachusettsUSA
| | - Rhoda Au
- Boston University Alzheimer's Disease Research Center and CTE CenterBoston University Chobanian & Avedisian School of MedicineBostonMassachusettsUSA
- Department of NeurologyBoston University Chobanian & Avedisian School of MedicineBostonMassachusettsUSA
- The Framingham Heart StudyFraminghamMassachusettsUSA
- Department of EpidemiologyBoston University School of Public HealthBostonMassachusettsUSA
- Department of Anatomy and NeurobiologyBoston University Chobanian & Avedisian School of MedicineBostonMassachusettsUSA
| | - Lee E. Goldstein
- Boston University Alzheimer's Disease Research Center and CTE CenterBoston University Chobanian & Avedisian School of MedicineBostonMassachusettsUSA
- Biostatistics and Epidemiology Data Analytics CenterBoston University School of Public HealthBostonMassachusettsUSA
- Department of OphthalmologyBoston University Chobanian & Avedisian School of MedicineBostonMassachusettsUSA
- Department of Biomedical, Electrical, and Computer EngineeringBoston University College of EngineeringBostonMassachusettsUSA
| | - Neil W. Kowall
- Boston University Alzheimer's Disease Research Center and CTE CenterBoston University Chobanian & Avedisian School of MedicineBostonMassachusettsUSA
- Department of NeurologyBoston University Chobanian & Avedisian School of MedicineBostonMassachusettsUSA
- US Department of Veterans AffairsVA Boston Healthcare SystemJamaica PlainMassachusettsUSA
- Department of Pathology and Laboratory MedicineBoston University Chobanian & Avedisian School of MedicineBostonMassachusettsUSA
| | - Ronald Killiany
- Boston University Alzheimer's Disease Research Center and CTE CenterBoston University Chobanian & Avedisian School of MedicineBostonMassachusettsUSA
- Department of Anatomy and NeurobiologyBoston University Chobanian & Avedisian School of MedicineBostonMassachusettsUSA
- Center for Biomedical ImagingBoston University Chobanian & Avedisian School of MedicineBostonMassachusettsUSA
| | - Robert A. Stern
- Boston University Alzheimer's Disease Research Center and CTE CenterBoston University Chobanian & Avedisian School of MedicineBostonMassachusettsUSA
- Department of NeurologyBoston University Chobanian & Avedisian School of MedicineBostonMassachusettsUSA
- Department of Anatomy and NeurobiologyBoston University Chobanian & Avedisian School of MedicineBostonMassachusettsUSA
- Department of NeurosurgeryBoston University Chobanian & Avedisian School of MedicineBostonMassachusettsUSA
| | - Thor D. Stein
- Boston University Alzheimer's Disease Research Center and CTE CenterBoston University Chobanian & Avedisian School of MedicineBostonMassachusettsUSA
- US Department of Veterans AffairsVA Boston Healthcare SystemJamaica PlainMassachusettsUSA
- Department of Pathology and Laboratory MedicineBoston University Chobanian & Avedisian School of MedicineBostonMassachusettsUSA
- US Department of Veterans AffairsVA Bedford Healthcare SystemBedfordMassachusettsUSA
| | - Ann C. McKee
- Boston University Alzheimer's Disease Research Center and CTE CenterBoston University Chobanian & Avedisian School of MedicineBostonMassachusettsUSA
- Department of NeurologyBoston University Chobanian & Avedisian School of MedicineBostonMassachusettsUSA
- US Department of Veterans AffairsVA Boston Healthcare SystemJamaica PlainMassachusettsUSA
- Department of Pathology and Laboratory MedicineBoston University Chobanian & Avedisian School of MedicineBostonMassachusettsUSA
- US Department of Veterans AffairsVA Bedford Healthcare SystemBedfordMassachusettsUSA
| | - Wei Qiao Qiu
- Boston University Alzheimer's Disease Research Center and CTE CenterBoston University Chobanian & Avedisian School of MedicineBostonMassachusettsUSA
- Department of PsychiatryBoston University Chobanian & Avedisian School of MedicineBostonMassachusettsUSA
- Department of Pharmacology and Experimental TherapeuticsBoston University Chobanian & Avedisian School of MedicineBostonMassachusettsUSA
| | - Jesse Mez
- Boston University Alzheimer's Disease Research Center and CTE CenterBoston University Chobanian & Avedisian School of MedicineBostonMassachusettsUSA
- Department of NeurologyBoston University Chobanian & Avedisian School of MedicineBostonMassachusettsUSA
| | - Michael L. Alosco
- Boston University Alzheimer's Disease Research Center and CTE CenterBoston University Chobanian & Avedisian School of MedicineBostonMassachusettsUSA
- Department of NeurologyBoston University Chobanian & Avedisian School of MedicineBostonMassachusettsUSA
| |
Collapse
|
15
|
Archer DB, Schilling K, Shashikumar N, Jasodanand V, Moore EE, Pechman KR, Bilgel M, Beason‐Held LL, An Y, Shafer A, Ferrucci L, Risacher SL, Gifford KA, Landman BA, Jefferson AL, Saykin AJ, Resnick SM, Hohman TJ. Leveraging longitudinal diffusion MRI data to quantify differences in white matter microstructural decline in normal and abnormal aging. Alzheimers Dement (Amst) 2023; 15:e12468. [PMID: 37780863 PMCID: PMC10540270 DOI: 10.1002/dad2.12468] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 03/30/2023] [Revised: 06/27/2023] [Accepted: 07/05/2023] [Indexed: 10/03/2023]
Abstract
Introduction It is unclear how rates of white matter microstructural decline differ between normal aging and abnormal aging. Methods Diffusion MRI data from several well-established longitudinal cohorts of aging (Alzheimer's Disease Neuroimaging Initiative [ADNI], Baltimore Longitudinal Study of Aging [BLSA], Vanderbilt Memory & Aging Project [VMAP]) were free-water corrected and harmonized. This dataset included 1723 participants (age at baseline: 72.8 ± 8.87 years, 49.5% male) and 4605 imaging sessions (follow-up time: 2.97 ± 2.09 years, follow-up range: 1-13 years, mean number of visits: 4.42 ± 1.98). Differences in white matter microstructural decline in normal and abnormal agers was assessed. Results While we found a global decline in white matter in normal/abnormal aging, we found that several white matter tracts (e.g., cingulum bundle) were vulnerable to abnormal aging. Conclusions There is a prevalent role of white matter microstructural decline in aging, and future large-scale studies in this area may further refine our understanding of the underlying neurodegenerative processes. HIGHLIGHTS Longitudinal data were free-water corrected and harmonized.Global effects of white matter decline were seen in normal and abnormal aging.The free-water metric was most vulnerable to abnormal aging.Cingulum free-water was the most vulnerable to abnormal aging.
Collapse
Affiliation(s)
- Derek B. Archer
- Vanderbilt Memory and Alzheimer's CenterVanderbilt University School of MedicineNashvilleTennesseeUSA
- Vanderbilt Genetics InstituteVanderbilt University Medical CenterNashvilleTennesseeUSA
| | - Kurt Schilling
- Vanderbilt University Institute of Imaging ScienceVanderbilt University Medical CenterNashvilleTennesseeUSA
- Department of Radiology & Radiological SciencesVanderbilt University Medical CenterNashvilleTennesseeUSA
| | - Niranjana Shashikumar
- Vanderbilt Memory and Alzheimer's CenterVanderbilt University School of MedicineNashvilleTennesseeUSA
| | - Varuna Jasodanand
- Vanderbilt Memory and Alzheimer's CenterVanderbilt University School of MedicineNashvilleTennesseeUSA
| | - Elizabeth E. Moore
- Vanderbilt Memory and Alzheimer's CenterVanderbilt University School of MedicineNashvilleTennesseeUSA
| | - Kimberly R. Pechman
- Vanderbilt Memory and Alzheimer's CenterVanderbilt University School of MedicineNashvilleTennesseeUSA
| | - Murat Bilgel
- Laboratory of Behavioral NeuroscienceNational Institute on AgingNational Institutes of HealthBaltimoreMarylandUSA
| | - Lori L. Beason‐Held
- Laboratory of Behavioral NeuroscienceNational Institute on AgingNational Institutes of HealthBaltimoreMarylandUSA
| | - Yang An
- Laboratory of Behavioral NeuroscienceNational Institute on AgingNational Institutes of HealthBaltimoreMarylandUSA
| | - Andrea Shafer
- Laboratory of Behavioral NeuroscienceNational Institute on AgingNational Institutes of HealthBaltimoreMarylandUSA
| | - Luigi Ferrucci
- Longitudinal Studies Section, Translational Gerontology BranchNational Institute on AgingBaltimoreMDUSA
| | - Shannon L. Risacher
- Indiana University School of MedicineIndianapolisIndianaUSA
- Indiana Alzheimer's Disease Research CenterIndianapolisIndianaUSA
| | - Katherine A. Gifford
- Vanderbilt Memory and Alzheimer's CenterVanderbilt University School of MedicineNashvilleTennesseeUSA
| | - Bennett A. Landman
- Vanderbilt University Institute of Imaging ScienceVanderbilt University Medical CenterNashvilleTennesseeUSA
- Department of Radiology & Radiological SciencesVanderbilt University Medical CenterNashvilleTennesseeUSA
- Department of Biomedical EngineeringVanderbilt UniversityNashvilleTennesseeUSA
- Department of Electrical and Computer EngineeringVanderbilt UniversityNashvilleTennesseeUSA
| | - Angela L. Jefferson
- Vanderbilt Memory and Alzheimer's CenterVanderbilt University School of MedicineNashvilleTennesseeUSA
- Department of MedicineVanderbilt University Medical CenterNashvilleTennesseeUSA
| | - Andrew J. Saykin
- Indiana University School of MedicineIndianapolisIndianaUSA
- Indiana Alzheimer's Disease Research CenterIndianapolisIndianaUSA
| | - Susan M. Resnick
- Laboratory of Behavioral NeuroscienceNational Institute on AgingNational Institutes of HealthBaltimoreMarylandUSA
| | - Timothy J. Hohman
- Vanderbilt Memory and Alzheimer's CenterVanderbilt University School of MedicineNashvilleTennesseeUSA
- Vanderbilt Genetics InstituteVanderbilt University Medical CenterNashvilleTennesseeUSA
| | | |
Collapse
|
16
|
Cummings J. Meaningful benefit and minimal clinically important difference (MCID) in Alzheimer's disease: Open peer commentary. Alzheimers Dement (N Y) 2023; 9:e12411. [PMID: 37521521 PMCID: PMC10372384 DOI: 10.1002/trc2.12411] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 06/23/2023] [Accepted: 06/27/2023] [Indexed: 08/01/2023]
Abstract
Introduction Approval of the anti-amyloid monoclonal antibodies has stimulated an important discussion of the value to be placed on the magnitude of slowing achieved by treatment compared to placebo. Methods The minimal clinically important difference (MCID) was reviewed in the context of other measures and analyses that provide perspective on the meaningfulness of treatment responses. Results TheMCID is a clinician-anchored approach to making this determination. The MCID applies best to symptomatic therapies for which the drug-placebo difference remains constant. Disease-modifying therapies produce a progressive divergence of drug and placebo trajectories; early in the course the MCID would not be achieved, later the MCID will be achieved, and with continuing therapy the MCID will be exceeded. Clinicians are not the only stakeholders involved in determining the value proposition of slowing disease progression. Patient-reported outcomes and caregiver-related measures offer important complementary insights. Analytic approaches also widen the perspective on the observed drug-placebo differences. Risk ratios, numbers needed to treat versus number needed to harm, time-to-event analyses, and predictive benefits based on biomarkers all add depth to the discussion. Discussion Multiple stakeholder perspectives are needed to determine the importance to be attributed to the therapeutic changes observed with monoclonal antibody therapies and other emerging treatments.
Collapse
Affiliation(s)
- Jeffrey Cummings
- Chambers‐Grundy Center for Transformative NeuroscienceDepartment of Brain HealthSchool of Integrated Health SciencesUniversity of Nevada Las Vegas (UNLV)Las VegasNevadaUSA
| |
Collapse
|
17
|
Vogelgsang J, Dan S, Lally AP, Chatigny M, Vempati S, Abston J, Durning PT, Oakley DH, McCoy TH, Klengel T, Berretta S. Dimensional clinical phenotyping using post-mortem brain donor medical records: post-mortem RDoC profiling is associated with Alzheimer's disease neuropathology. Alzheimers Dement (Amst) 2023; 15:e12464. [PMID: 37745891 PMCID: PMC10517223 DOI: 10.1002/dad2.12464] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Received: 05/02/2023] [Revised: 06/30/2023] [Accepted: 07/07/2023] [Indexed: 09/26/2023]
Abstract
Introduction Transdiagnostic dimensional phenotypes are essential to investigate the relationship between continuous symptom dimensions and pathological changes. This is a fundamental challenge to post-mortem work, as assessments of phenotypic concepts need to rely on existing records. Methods We adapted well-validated methodologies to compute National Institute of Mental Health Research Domain Criteria (RDoC) scores using natural language processing (NLP) from electronic health records (EHRs) obtained from post-mortem brain donors and tested whether cognitive domain scores were associated with Alzheimer's disease neuropathological measures. Results Our results confirm an association of EHR-derived cognitive scores with neuropathological findings. Notably, higher neuropathological load, particularly neuritic plaques, was associated with higher cognitive burden scores in the frontal (ß = 0.38, P = 0.0004), parietal (ß = 0.35, P = 0.0008), temporal (ß = 0.37, P = 0.0004) and occipital (ß = 0.37, P = 0.0003) lobes. Discussion This proof-of-concept study supports the validity of NLP-based methodologies to obtain quantitative measures of RDoC clinical domains from post-mortem EHR. The associations may accelerate post-mortem brain research beyond classical case-control designs.
Collapse
Affiliation(s)
- Jonathan Vogelgsang
- Department of Psychiatry, McLean HospitalHarvard Medical SchoolBelmontMassachusettsUSA
| | - Shu Dan
- Department of Psychiatry, McLean HospitalHarvard Medical SchoolBelmontMassachusettsUSA
| | - Anna P. Lally
- Department of Psychiatry, McLean HospitalHarvard Medical SchoolBelmontMassachusettsUSA
| | - Michael Chatigny
- Department of Psychiatry, McLean HospitalHarvard Medical SchoolBelmontMassachusettsUSA
- Harvard Brain Tissue Resource Center, McLean HospitalHarvard Medical SchoolBelmontMassachusettsUSA
| | - Sangeetha Vempati
- Department of Psychiatry, McLean HospitalHarvard Medical SchoolBelmontMassachusettsUSA
| | - Joshua Abston
- Department of Psychiatry, McLean HospitalHarvard Medical SchoolBelmontMassachusettsUSA
| | - Peter T. Durning
- Department of Psychiatry, McLean HospitalHarvard Medical SchoolBelmontMassachusettsUSA
| | - Derek H. Oakley
- Harvard Brain Tissue Resource Center, McLean HospitalHarvard Medical SchoolBelmontMassachusettsUSA
- Department of Pathology, Massachusetts General HospitalHarvard Medical SchoolBostonMassachusettsUSA
| | - Thomas H. McCoy
- Department of Psychiatry and Medicine, Massachusetts General HospitalHarvard Medical SchoolBostonMassachusettsUSA
| | - Torsten Klengel
- Department of Psychiatry, McLean HospitalHarvard Medical SchoolBelmontMassachusettsUSA
- Harvard Brain Tissue Resource Center, McLean HospitalHarvard Medical SchoolBelmontMassachusettsUSA
| | - Sabina Berretta
- Department of Psychiatry, McLean HospitalHarvard Medical SchoolBelmontMassachusettsUSA
- Harvard Brain Tissue Resource Center, McLean HospitalHarvard Medical SchoolBelmontMassachusettsUSA
| |
Collapse
|
18
|
So RJ, Cevallos A, Pile M, Biju K, Perez‐Heydrich C, Padova D, Walker C, Schubert M, Agrawal Y. Quantitative vestibular assessment: The development and validation of a novel, remote video head impulse test against in-clinic measurements. Laryngoscope Investig Otolaryngol 2023; 8:758-762. [PMID: 37342103 PMCID: PMC10278116 DOI: 10.1002/lio2.1069] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2023] [Revised: 02/28/2023] [Accepted: 04/09/2023] [Indexed: 06/22/2023] Open
Abstract
Objectives To develop a novel remote head impulse test (rHIT), and to provide preliminary data validating the rHIT vestibular-ocular reflex (VOR) gains against the in-clinic vHIT. Methods A convenience sample of 10 patients referred for vestibular assessment at our institution was recruited. In-clinic vHIT was used to quantify lateral VOR gains. Patients subsequently underwent an rHIT protocol, whereby patients performed active, lateral head rotations while their eyes and heads were recorded using a laptop camera and video-conferencing software. The vHIT and rHIT VOR gains were compared using paired t-tests, and a Pearson correlation coefficient between the gains was calculated. Absolute accuracy, sensitivity, and specificity of the rHIT were additionally calculated. Results Of the 10 patients recruited, 4 were male, and the average ± standard deviation (SD) age was 61.4 ± 15.3 years. As determined by the vHIT, 2 patients had normal bilateral VOR gains, 6 with unilateral vestibular hypofunction, and 2 with bilateral vestibular hypofunction. The correlation between the rHIT and vHIT gains was 0.73 (p < .001). The rHIT exhibited an absolute accuracy of 75.0%, sensitivity of 70.0%, and specificity of 80.0%. When ears had a vHIT VOR gain less than 0.40, the rHIT exhibited 100.0% accuracy. Conversely, 60.0% of deficient ears with vHIT VOR gains greater than 0.40 were incorrectly categorized by the rHIT. Conclusion The rHIT may be better suited for detecting more severe vestibular deficiencies. Future iterations of the rHIT should aim to increase the video frame-rate capabilities to detect subtler VOR impairments. Level of Evidence 4.
Collapse
Affiliation(s)
- Raymond J. So
- Department of OtolaryngologyJohns Hopkins University School of MedicineBaltimoreMarylandUSA
- Medical Student Training in Aging Research Program, Department of Geriatric Medicine and GerontologyJohns Hopkins University School of MedicineBaltimoreMarylandUSA
| | - Ashley Cevallos
- Department of OtolaryngologyJohns Hopkins University School of MedicineBaltimoreMarylandUSA
| | - Macie Pile
- Department of OtolaryngologyJohns Hopkins University School of MedicineBaltimoreMarylandUSA
| | - Kevin Biju
- Department of OtolaryngologyJohns Hopkins University School of MedicineBaltimoreMarylandUSA
| | - Carlos Perez‐Heydrich
- Department of OtolaryngologyJohns Hopkins University School of MedicineBaltimoreMarylandUSA
| | - Dominic Padova
- Department of OtolaryngologyJohns Hopkins University School of MedicineBaltimoreMarylandUSA
| | - Courtney Walker
- Department of OtolaryngologyJohns Hopkins University School of MedicineBaltimoreMarylandUSA
| | - Michael Schubert
- Department of OtolaryngologyJohns Hopkins University School of MedicineBaltimoreMarylandUSA
| | - Yuri Agrawal
- Department of OtolaryngologyJohns Hopkins University School of MedicineBaltimoreMarylandUSA
| |
Collapse
|
19
|
Ishii T, Ruiz‐Torruella M, Kim JY, Kanzaki H, Albassam A, Wisitrasameewong W, Shindo S, Pierrelus R, Heidari A, Kandalam U, Nakamura S, Movila A, Minond D, Kawai T. Soluble Sema4D cleaved from osteoclast precursors by TACE suppresses osteoblastogenesis. J Cell Mol Med 2023; 27:1750-1756. [PMID: 37170687 PMCID: PMC10273054 DOI: 10.1111/jcmm.17416] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2022] [Revised: 04/27/2022] [Accepted: 05/03/2022] [Indexed: 05/13/2023] Open
Abstract
Bone remodelling is mediated by orchestrated communication between osteoclasts and osteoblasts which, in part, is regulated by coupling and anti-coupling factors. Amongst formally known anti-coupling factors, Semaphorin 4D (Sema4D), produced by osteoclasts, plays a key role in downmodulating osteoblastogenesis. Sema4D is produced in both membrane-bound and soluble forms; however, the mechanism responsible for producing sSema4D from osteoclasts is unknown. Sema4D, TACE and MT1-MMP are all expressed on the surface of RANKL-primed osteoclast precursors. However, only Sema4D and TACE were colocalized, not Sema4D and MT1-MMP. When TACE and MT1-MMP were either chemically inhibited or suppressed by siRNA, TACE was found to be more engaged in shedding Sema4D. Anti-TACE-mAb inhibited sSema4D release from osteoclast precursors by ~90%. Supernatant collected from osteoclast precursors (OC-sup) suppressed osteoblastogenesis from MC3T3-E1 cells, as measured by alkaline phosphatase activity, but OC-sup harvested from the osteoclast precursors treated with anti-TACE-mAb restored osteoblastogenesis activity in a manner that compensates for diminished sSema4D. Finally, systemic administration of anti-TACE-mAb downregulated the generation of sSema4D in the mouse model of critical-sized bone defect, whereas local injection of recombinant sSema4D to anti-TACE-mAb-treated defect upregulated local osteoblastogenesis. Therefore, a novel pathway is proposed whereby TACE-mediated shedding of Sema4D expressed on the osteoclast precursors generates functionally active sSema4D to suppress osteoblastogenesis.
Collapse
Affiliation(s)
- Takenobu Ishii
- Department of OrthodonticsTokyo Dental CollegeChibaJapan
| | | | - Jae Young Kim
- Department of ProsthodonticsYonsei University Dental HospitalSeoulKorea
| | - Hiroyuki Kanzaki
- Department of orthodontics, School of Dental MedicineTsurumi UniversityYokohamaJapan
| | - Abdullah Albassam
- Department of Endodontics, Faculty of DentistryKing Abdulaziz UniversityJeddahSaudi Arabia
| | | | - Satoru Shindo
- Department of Oral Science and Translational Research, College of Dental MedicineNova Southeastern UniversityFort LauderdaleFloridaUSA
| | - Roodelyne Pierrelus
- Department of Oral Science and Translational Research, College of Dental MedicineNova Southeastern UniversityFort LauderdaleFloridaUSA
| | - Alireza Heidari
- Department of Oral Science and Translational Research, College of Dental MedicineNova Southeastern UniversityFort LauderdaleFloridaUSA
| | - Umadevi Kandalam
- Department of Oral Science and Translational Research, College of Dental MedicineNova Southeastern UniversityFort LauderdaleFloridaUSA
| | - Shin Nakamura
- Department of Oral Science and Translational Research, College of Dental MedicineNova Southeastern UniversityFort LauderdaleFloridaUSA
| | - Alexandru Movila
- Department of Oral Science and Translational Research, College of Dental MedicineNova Southeastern UniversityFort LauderdaleFloridaUSA
| | - Dmitriy Minond
- Department of Pharmaceutical Sciences, College of PharmacyNova Southeastern UniversityFort LauderdaleFloridaUSA
| | - Toshihisa Kawai
- Department of Oral Science and Translational Research, College of Dental MedicineNova Southeastern UniversityFort LauderdaleFloridaUSA
- Center for Collaborative Research, Cell Therapy InstituteNova Southeastern UniversityFort LauderdaleFloridaUSA
| |
Collapse
|
20
|
Huang X, Li Y, Fowler C, Doecke JD, Lim YY, Drysdale C, Zhang V, Park K, Trounson B, Pertile K, Rumble R, Pickering JW, Rissman RA, Sarsoza F, Abdel‐Latif S, Lin Y, Doré V, Villemagne V, Rowe CC, Fripp J, Martins R, Wiley JS, Maruff P, Mintzer JE, Masters CL, Gu BJ. Leukocyte surface biomarkers implicate deficits of innate immunity in sporadic Alzheimer's disease. Alzheimers Dement 2023; 19:2084-2094. [PMID: 36349985 PMCID: PMC10166765 DOI: 10.1002/alz.12813] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2022] [Revised: 08/24/2022] [Accepted: 09/02/2022] [Indexed: 11/10/2022]
Abstract
INTRODUCTION Blood-based diagnostics and prognostics in sporadic Alzheimer's disease (AD) are important for identifying at-risk individuals for therapeutic interventions. METHODS In three stages, a total of 34 leukocyte antigens were examined by flow cytometry immunophenotyping. Data were analyzed by logistic regression and receiver operating characteristic (ROC) analyses. RESULTS We identified leukocyte markers differentially expressed in the patients with AD. Pathway analysis revealed a complex network involving upregulation of complement inhibition and downregulation of cargo receptor activity and Aβ clearance. A proposed panel including four leukocyte markers - CD11c, CD59, CD91, and CD163 - predicts patients' PET Aβ status with an area under the curve (AUC) of 0.93 (0.88 to 0.97). CD163 was the top performer in preclinical models. These findings have been validated in two independent cohorts. CONCLUSION Our finding of changes on peripheral leukocyte surface antigens in AD implicates the deficit in innate immunity. Leukocyte-based biomarkers prove to be both sensitive and practical for AD screening and diagnosis.
Collapse
Affiliation(s)
- Xin Huang
- The Florey Institute of Neurosciencethe University of MelbourneParkvilleVictoriaAustralia
| | - Yihan Li
- The Florey Institute of Neurosciencethe University of MelbourneParkvilleVictoriaAustralia
| | - Christopher Fowler
- The Florey Institute of Neurosciencethe University of MelbourneParkvilleVictoriaAustralia
| | - James D. Doecke
- The Australian e‐Health Research CentreCSIROBrisbaneQueenslandAustralia
| | - Yen Ying Lim
- Turner Institute for Brain and Mental HealthSchool of Psychological SciencesMonash UniversityClaytonVictoriaAustralia
| | - Candace Drysdale
- The Florey Institute of Neurosciencethe University of MelbourneParkvilleVictoriaAustralia
| | - Vicky Zhang
- The Florey Institute of Neurosciencethe University of MelbourneParkvilleVictoriaAustralia
| | - Keunha Park
- The Florey Institute of Neurosciencethe University of MelbourneParkvilleVictoriaAustralia
| | - Brett Trounson
- The Florey Institute of Neurosciencethe University of MelbourneParkvilleVictoriaAustralia
| | - Kelly Pertile
- The Florey Institute of Neurosciencethe University of MelbourneParkvilleVictoriaAustralia
| | - Rebecca Rumble
- The Florey Institute of Neurosciencethe University of MelbourneParkvilleVictoriaAustralia
| | - John W. Pickering
- Department of MedicineUniversity of OtagoNew Zealand and Department of Emergency MedicineChristchurch HospitalChristchurchNew Zealand
| | - Robert A. Rissman
- Department of NeurosciencesUniversity of CaliforniaSan DiegoCaliforniaUSA
| | - Floyd Sarsoza
- Department of NeurosciencesUniversity of CaliforniaSan DiegoCaliforniaUSA
| | - Sara Abdel‐Latif
- Alzheimer's Therapeutic Research InstituteUniversity of Southern CaliforniaSan DiegoCaliforniaUSA
| | - Yong Lin
- National Clinical Research Center for Aging and MedicineHuashan HospitalFudan UniversityShanghaiChina
| | - Vincent Doré
- The Australian e‐Health Research CentreCSIROBrisbaneQueenslandAustralia
- Department of Molecular Imaging & Therapy, Austin Health, Melbourne, Australia, and Department of Medicinethe University of MelbourneMelbourneAustralia
| | - Victor Villemagne
- Department of Molecular Imaging & Therapy, Austin Health, Melbourne, Australia, and Department of Medicinethe University of MelbourneMelbourneAustralia
| | - Christopher C. Rowe
- Department of Molecular Imaging & Therapy, Austin Health, Melbourne, Australia, and Department of Medicinethe University of MelbourneMelbourneAustralia
| | - Jurgen Fripp
- The Australian e‐Health Research CentreCSIROBrisbaneQueenslandAustralia
| | - Ralph Martins
- Centre of Excellence for Alzheimer's Disease Research and CareSchool of Medical and Health SciencesEdith Cowan UniversityJoondalupWestern AustraliaAustralia
| | - James S. Wiley
- The Florey Institute of Neurosciencethe University of MelbourneParkvilleVictoriaAustralia
| | - Paul Maruff
- The Florey Institute of Neurosciencethe University of MelbourneParkvilleVictoriaAustralia
- CogState Ltd.MelbourneVictoriaAustralia
| | | | - Colin L. Masters
- The Florey Institute of Neurosciencethe University of MelbourneParkvilleVictoriaAustralia
| | - Ben J. Gu
- The Florey Institute of Neurosciencethe University of MelbourneParkvilleVictoriaAustralia
- National Clinical Research Center for Aging and MedicineHuashan HospitalFudan UniversityShanghaiChina
| |
Collapse
|
21
|
Cummings J, Zhou Y, Lee G, Zhong K, Fonseca J, Cheng F. Alzheimer's disease drug development pipeline: 2023. Alzheimers Dement (N Y) 2023; 9:e12385. [PMID: 37251912 PMCID: PMC10210334 DOI: 10.1002/trc2.12385] [Citation(s) in RCA: 57] [Impact Index Per Article: 57.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 03/14/2023] [Revised: 03/23/2023] [Accepted: 03/23/2023] [Indexed: 05/31/2023]
Abstract
Introduction Drugs that prevent the onset, slow progression, or improve cognitive and behavioral symptoms of Alzheimer's disease (AD) are needed. Methods We searched ClinicalTrials.gov for all current Phase 1, 2 and 3 clinical trials for AD and mild cognitive impairment (MCI) attributed to AD. We created an automated computational database platform to search, archive, organize, and analyze the derived data. The Common Alzheimer's Disease Research Ontology (CADRO) was used to identify treatment targets and drug mechanisms. Results On the index date of January 1, 2023, there were 187 trials assessing 141 unique treatments for AD. Phase 3 included 36 agents in 55 trials; 87 agents were in 99 Phase 2 trials; and Phase 1 had 31 agents in 33 trials. Disease-modifying therapies were the most common drugs comprising 79% of drugs in trials. Twenty-eight percent of candidate therapies are repurposed agents. Populating all current Phase 1, 2, and 3 trials will require 57,465 participants. Discussion The AD drug development pipeline is advancing agents directed at a variety of target processes. HIGHLIGHTS There are currently 187 trials assessing 141 drugs for the treatment of Alzheimer's disease (AD).Drugs in the AD pipeline address a variety of pathological processes.More than 57,000 participants will be required to populate all currently registered trials.
Collapse
Affiliation(s)
- Jeffrey Cummings
- Department of Brain HealthChambers‐Grundy Center for Transformative NeuroscienceSchool of Integrated Health SciencesUniversity of Nevada, Las Vegas (UNLV)Las VegasNevadaUSA
- Department of Computer ScienceHoward R. Hughes College of EngineeringUniversity of Nevada, Las Vegas (UNLV)Las VegasNevadaUSA
| | - Yadi Zhou
- Genomic Medicine InstituteLerner Research InstituteCleveland ClinicClevelandOhioUSA
| | - Garam Lee
- Department of Brain HealthSchool of Integrated Health SciencesUniversity of Nevada, Las Vegas (UNLV)Las VegasNevadaUSA
| | - Kate Zhong
- Department of Brain HealthChambers‐Grundy Center for Transformative NeuroscienceSchool of Integrated Health SciencesUniversity of Nevada, Las Vegas (UNLV)Las VegasNevadaUSA
- Department of Computer ScienceHoward R. Hughes College of EngineeringUniversity of Nevada, Las Vegas (UNLV)Las VegasNevadaUSA
| | - Jorge Fonseca
- Department of Molecular MedicineCleveland Clinic Lerner College of MedicineCase Western Reserve UniversityClevelandOhioUSA
| | - Feixiong Cheng
- Genomic Medicine InstituteLerner Research InstituteCleveland ClinicClevelandOhioUSA
- Department of Molecular MedicineCleveland Clinic Lerner College of MedicineCase Western Reserve UniversityClevelandOhioUSA
- Case Comprehensive Cancer CenterCase Western Reserve University School of MedicineClevelandOhioUSA
| |
Collapse
|
22
|
Pena‐Garcia A, Richards R, Richards M, Campbell C, Mosley H, Asper J, Eliacin J, Polsinelli A, Apostolova L, Hendrie H, Tackett A, Elliott C, Van Heiden S, Gao S, Saykin A, Wang S. Accelerating diversity in Alzheimer's disease research by partnering with a community advisory board. Alzheimers Dement (N Y) 2023; 9:e12400. [PMID: 37256164 PMCID: PMC10225742 DOI: 10.1002/trc2.12400] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 02/24/2023] [Revised: 04/18/2023] [Accepted: 05/03/2023] [Indexed: 06/01/2023]
Abstract
Introduction Community advisory boards (CABs) and researcher partnerships present a promising opportunity to accelerate enrollment of underrepresented groups (URGs). We outline the framework for how the CAB and researchers at the Indiana Alzheimer's Disease Research Center (IADRC) partnered to accelerate URG participation in AD neuroimaging research. Methods CAB and the IADRC researchers partnered to increase the CAB's impact on URG study enrollment through community and research interactions. Community interactions included the CAB collaboratively building a network of URG focused community organizations and collaborating with those URG-focused organizations to host IADRC outreach and recruitment events. Research interactions included direct impact (CAB members referring themselves or close contacts as participants) and strategic impact, mainly by the CAB working with researchers to develop and refine URG focused outreach and recruitment strategies for IADRC and affiliated studies to increase URG representation. We created a database infrastructure to measure how these interactions impacted URG study enrollment. Results Out of the 354 URG research referrals made to the IADRC between October 2019 and December 2022, 267 referrals were directly referred by the CAB (N = 36) or from community events in which CAB members organized and/or volunteered at (N = 231). Out of these 267 referrals, 34 were enrolled in IADRC and 2 were enrolled in Indiana University Longitudinal Early Onset AD Study (IU LEADS). Of note, both studies require the prospective participants to be willing to do MRI and PET scans. As of December 2022, 30 out of the 34 enrolled participants have received a consensus diagnosis; the majority were cognitively normal (64.7%), with the remainder having mild cognitive impairment (17.6%) or early-stage AD (2.9%). Discussion The IADRC CAB-researcher partnership had a measurable impact on the enrollment of African American/Black adults in AD neuroimaging studies. Future studies will need to test whether this conceptual model works for other sites and for other URGs.
Collapse
Affiliation(s)
- Alex Pena‐Garcia
- Marian University College of Osteopathic MedicineIndianapolisIndianaUSA
| | - Ralph Richards
- Indiana University Alzheimer's Disease Research Center Community Advisory BoardIndiana University School of MedicineIndianapolisIndianaUSA
| | - Mollie Richards
- Indiana University Alzheimer's Disease Research Center Community Advisory BoardIndiana University School of MedicineIndianapolisIndianaUSA
| | - Christopher Campbell
- Indiana University Alzheimer's Disease Research Center Community Advisory BoardIndiana University School of MedicineIndianapolisIndianaUSA
| | - Hank Mosley
- Indiana University Alzheimer's Disease Research Center Community Advisory BoardIndiana University School of MedicineIndianapolisIndianaUSA
| | - Joseph Asper
- Marian University College of Osteopathic MedicineIndianapolisIndianaUSA
| | - Johanne Eliacin
- Department of Internal General MedicineIndiana University School of MedicineIndianapolisIndianaUSA
- Indiana Alzheimer's Disease Research CenterIndiana University School of MedicineIndianapolisIndianaUSA
- VA HSR&D Center for Health Information and CommunicationRoudebush VA Medical CenterIndianapolisIndianaUSA
| | - Angelina Polsinelli
- Indiana University Alzheimer's Disease Research Center Community Advisory BoardIndiana University School of MedicineIndianapolisIndianaUSA
- Department of NeurologyIndiana University School of MedicineIndianapolisIndianaUSA
| | - Liana Apostolova
- Department of NeurologyIndiana University School of MedicineIndianapolisIndianaUSA
| | - Hugh Hendrie
- Department of PsychiatryIndiana University School of MedicineIndianapolisIndianaUSA
| | - Andrew Tackett
- Indiana Alzheimer's Disease Research CenterIndiana University School of MedicineIndianapolisIndianaUSA
| | - Caprice Elliott
- Indiana Alzheimer's Disease Research CenterIndiana University School of MedicineIndianapolisIndianaUSA
- Department of RadiologyIndiana University School of MedicineIndianapolisIndianaUSA
| | - Sarah Van Heiden
- Indiana Alzheimer's Disease Research CenterIndiana University School of MedicineIndianapolisIndianaUSA
- Department of RadiologyIndiana University School of MedicineIndianapolisIndianaUSA
| | - Sujuan Gao
- Indiana Alzheimer's Disease Research CenterIndiana University School of MedicineIndianapolisIndianaUSA
- Department of BiostatisticsIndiana University School of MedicineIndianapolisIndianaUSA
| | - Andrew Saykin
- Indiana Alzheimer's Disease Research CenterIndiana University School of MedicineIndianapolisIndianaUSA
- Department of RadiologyIndiana University School of MedicineIndianapolisIndianaUSA
| | - Sophia Wang
- Indiana Alzheimer's Disease Research CenterIndiana University School of MedicineIndianapolisIndianaUSA
- Department of PsychiatryIndiana University School of MedicineIndianapolisIndianaUSA
| | | |
Collapse
|
23
|
Yang Y, Schilling K, Shashikumar N, Jasodanand V, Moore EE, Pechman KR, Bilgel M, Beason‐Held LL, An Y, Shafer A, Risacher SL, Landman BA, Jefferson AL, Saykin AJ, Resnick SM, Hohman TJ, Archer DB. White matter microstructural metrics are sensitively associated with clinical staging in Alzheimer's disease. Alzheimers Dement (Amst) 2023; 15:e12425. [PMID: 37213219 PMCID: PMC10192723 DOI: 10.1002/dad2.12425] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 11/18/2022] [Revised: 03/06/2023] [Accepted: 03/12/2023] [Indexed: 05/23/2023]
Abstract
Introduction White matter microstructure may be abnormal along the Alzheimer's disease (AD) continuum. Methods Diffusion magnetic resonance imaging (dMRI) data from the Alzheimer's Disease Neuroimaging Initiative (ADNI, n = 627), Baltimore Longitudinal Study of Aging (BLSA, n = 684), and Vanderbilt Memory & Aging Project (VMAP, n = 296) cohorts were free-water (FW) corrected and conventional, and FW-corrected microstructural metrics were quantified within 48 white matter tracts. Microstructural values were subsequently harmonized using the Longitudinal ComBat technique and inputted as independent variables to predict diagnosis (cognitively unimpaired [CU], mild cognitive impairment [MCI], AD). Models were adjusted for age, sex, race/ethnicity, education, apolipoprotein E (APOE) ε4 carrier status, and APOE ε2 carrier status. Results Conventional dMRI metrics were associated globally with diagnostic status; following FW correction, the FW metric itself exhibited global associations with diagnostic status, but intracellular metric associations were diminished. Discussion White matter microstructure is altered along the AD continuum. FW correction may provide further understanding of the white matter neurodegenerative process in AD. Highlights Longitudinal ComBat successfully harmonized large-scale diffusion magnetic resonance imaging (dMRI) metrics.Conventional dMRI metrics were globally sensitive to diagnostic status.Free-water (FW) correction mitigated intracellular associations with diagnostic status.The FW metric itself was globally sensitive to diagnostic status. Multivariate conventional and FW-corrected models may provide complementary information.
Collapse
Affiliation(s)
- Yisu Yang
- Vanderbilt Memory and Alzheimer's CenterVanderbilt University School of MedicineNashvilleTennesseeUSA
| | - Kurt Schilling
- Vanderbilt University Institute of Imaging ScienceVanderbilt University Medical CenterNashvilleTennesseeUSA
- Department of Radiology & Radiological SciencesVanderbilt University Medical CenterNashvilleTennesseeUSA
| | - Niranjana Shashikumar
- Vanderbilt Memory and Alzheimer's CenterVanderbilt University School of MedicineNashvilleTennesseeUSA
| | - Varuna Jasodanand
- Vanderbilt Memory and Alzheimer's CenterVanderbilt University School of MedicineNashvilleTennesseeUSA
| | - Elizabeth E. Moore
- Vanderbilt Memory and Alzheimer's CenterVanderbilt University School of MedicineNashvilleTennesseeUSA
| | - Kimberly R. Pechman
- Vanderbilt Memory and Alzheimer's CenterVanderbilt University School of MedicineNashvilleTennesseeUSA
| | - Murat Bilgel
- Laboratory of Behavioral NeuroscienceNational Institute on AgingNational Institutes of HealthBaltimoreMarylandUSA
| | - Lori L. Beason‐Held
- Laboratory of Behavioral NeuroscienceNational Institute on AgingNational Institutes of HealthBaltimoreMarylandUSA
| | - Yang An
- Laboratory of Behavioral NeuroscienceNational Institute on AgingNational Institutes of HealthBaltimoreMarylandUSA
| | - Andrea Shafer
- Laboratory of Behavioral NeuroscienceNational Institute on AgingNational Institutes of HealthBaltimoreMarylandUSA
| | - Shannon L. Risacher
- Indiana University School of MedicineIndianapolisIndianaUSA
- Indiana Alzheimer's Disease Research CenterIndianapolisIndianaUSA
| | - Bennett A. Landman
- Vanderbilt Memory and Alzheimer's CenterVanderbilt University School of MedicineNashvilleTennesseeUSA
- Vanderbilt University Institute of Imaging ScienceVanderbilt University Medical CenterNashvilleTennesseeUSA
- Department of Radiology & Radiological SciencesVanderbilt University Medical CenterNashvilleTennesseeUSA
- Department of Biomedical EngineeringVanderbilt UniversityNashvilleTennesseeUSA
- Department of Electrical and Computer EngineeringVanderbilt UniversityNashvilleTennesseeUSA
| | - Angela L. Jefferson
- Vanderbilt Memory and Alzheimer's CenterVanderbilt University School of MedicineNashvilleTennesseeUSA
- Vanderbilt Genetics InstituteVanderbilt University Medical CenterNashvilleTennesseeUSA
- Department of MedicineVanderbilt University Medical CenterNashvilleTennesseeUSA
| | - Andrew J. Saykin
- Indiana University School of MedicineIndianapolisIndianaUSA
- Indiana Alzheimer's Disease Research CenterIndianapolisIndianaUSA
| | - Susan M. Resnick
- Laboratory of Behavioral NeuroscienceNational Institute on AgingNational Institutes of HealthBaltimoreMarylandUSA
| | - Timothy J. Hohman
- Vanderbilt Memory and Alzheimer's CenterVanderbilt University School of MedicineNashvilleTennesseeUSA
- Vanderbilt Genetics InstituteVanderbilt University Medical CenterNashvilleTennesseeUSA
| | - Derek B. Archer
- Vanderbilt Memory and Alzheimer's CenterVanderbilt University School of MedicineNashvilleTennesseeUSA
- Vanderbilt Genetics InstituteVanderbilt University Medical CenterNashvilleTennesseeUSA
| | | |
Collapse
|
24
|
Tryon SC, Sakamoto IM, Kaigler KF, Gee G, Turner J, Bartley K, Fadel JR, Wilson MA. ChAT::Cre transgenic rats show sex-dependent altered fear behaviors, ultrasonic vocalizations and cholinergic marker expression. Genes Brain Behav 2023; 22:e12837. [PMID: 36636833 PMCID: PMC9994175 DOI: 10.1111/gbb.12837] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/26/2022] [Revised: 12/20/2022] [Accepted: 01/03/2023] [Indexed: 01/14/2023]
Abstract
The cholinergic system is a critical regulator of Pavlovian fear learning and extinction. As such, we have begun investigating the cholinergic system's involvement in individual differences in cued fear extinction using a transgenic ChAT::Cre rat model. The current study extends behavioral phenotyping of a transgenic ChAT::Cre rat line by examining both freezing behavior and ultrasonic vocalizations (USVs) during a Pavlovian cued fear learning and extinction paradigm. Freezing, 22 kHz USVs, and 50 kHz USVs were compared between male and female transgenic ChAT::Cre+ rats and their wildtype (Cre-) littermates during fear learning, contextual and cue-conditioned fear recall, cued fear extinction, and generalization to a novel tone. During contextual and cued fear recall ChAT::Cre+ rats froze slightly more than their Cre- littermates, and displayed significant sex differences in contextual and cue-conditioned freezing, 22 kHz USVs, and 50 kHz USVs. Females showed more freezing than males in fear recall trials, but fewer 22 kHz distress calls during fear learning and recall. Females also produced more 50 kHz USVs during exposure to the testing chambers prior to tone (or shock) presentation compared with males, but this effect was blunted in ChAT::Cre+ females. Corroborating previous studies, ChAT::Cre+ transgenic rats overexpressed vesicular acetylcholine transporter immunolabeling in basal forebrain, striatum, basolateral amygdala, and hippocampus, but had similar levels of acetylcholinesterase and numbers of ChAT+ neurons as Cre- rats. This study suggests that variance in behavior between ChAT::Cre+ and wildtype rats is sex dependent and advances theories that distinct neural circuits and processes regulate sexually divergent fear responses.
Collapse
Affiliation(s)
- Sarah C. Tryon
- Department of Pharmacology, Physiology & NeuroscienceUniversity of South Carolina School of MedicineColumbiaSouth CarolinaUSA
| | - Iris M. Sakamoto
- Department of Pharmacology, Physiology & NeuroscienceUniversity of South Carolina School of MedicineColumbiaSouth CarolinaUSA
| | - Kris F. Kaigler
- Department of Pharmacology, Physiology & NeuroscienceUniversity of South Carolina School of MedicineColumbiaSouth CarolinaUSA
| | - Gabriella Gee
- Department of Pharmacology, Physiology & NeuroscienceUniversity of South Carolina School of MedicineColumbiaSouth CarolinaUSA
| | - Jarrett Turner
- Department of Pharmacology, Physiology & NeuroscienceUniversity of South Carolina School of MedicineColumbiaSouth CarolinaUSA
| | - Katherine Bartley
- Department of Pharmacology, Physiology & NeuroscienceUniversity of South Carolina School of MedicineColumbiaSouth CarolinaUSA
| | - Jim R. Fadel
- Department of Pharmacology, Physiology & NeuroscienceUniversity of South Carolina School of MedicineColumbiaSouth CarolinaUSA
| | - Marlene A. Wilson
- Department of Pharmacology, Physiology & NeuroscienceUniversity of South Carolina School of MedicineColumbiaSouth CarolinaUSA
- Columbia VA Health Care SystemColumbiaSouth CarolinaUSA
| |
Collapse
|
25
|
Godrich D, Martin ER, Schellenberg G, Pericak‐Vance MA, Cuccaro M, Scott WK, Kukull W, Montine T, Beecham GW. Neuropathological lesions and their contribution to dementia and cognitive impairment in a heterogeneous clinical population. Alzheimers Dement 2022; 18:2403-2412. [PMID: 35142102 PMCID: PMC9360193 DOI: 10.1002/alz.12516] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/07/2021] [Revised: 09/14/2021] [Accepted: 09/22/2021] [Indexed: 01/31/2023]
Abstract
INTRODUCTION Alzheimer disease (AD) and related dementias are characterized by damage caused by neuropathological lesions in the brain. These include AD lesions (plaques and tangles) and non-AD lesions such as vascular injury or Lewy bodies. We report here an assessment of lesion association to dementia in a large clinic-based population. METHODS We identified 5272 individuals with neuropathological data from the National Alzheimer's Coordinating Center. Individual lesions, as well as a neuropathological composite score (NPCS) were tested for association with dementia, and both functional and neurocognitive impairment using regression models. RESULTS Most individuals exhibited mixed pathologies, especially AD lesions in combination with non-AD lesions. All lesion types were associated with one or more clinical outcomes; most even while controlling for AD pathology. The NPCS was also associated with clinical outcomes. DISCUSSION These data suggest mixed-type pathologies are extremely common in a clinic-based population and may contribute to dementia and cognitive impairment.
Collapse
Affiliation(s)
- Dana Godrich
- Dr. John T MacDonald Foundation Department of Human GeneticsMiller School of MedicineUniversity of MiamiMiamiFloridaUSA
| | - Eden R. Martin
- Dr. John T MacDonald Foundation Department of Human GeneticsMiller School of MedicineUniversity of MiamiMiamiFloridaUSA
- John P. Hussman Institute for Human GenomicsMiller School of MedicineUniversity of MiamiMiamiFloridaUSA
| | - Gerard Schellenberg
- Penn Neurodegeneration Genomics CenterDepartment of Pathology and Laboratory MedicineUniversity of Pennsylvania Perelman School of MedicinePhiladelphiaPennsylvaniaUSA
| | - Margaret A. Pericak‐Vance
- Dr. John T MacDonald Foundation Department of Human GeneticsMiller School of MedicineUniversity of MiamiMiamiFloridaUSA
- John P. Hussman Institute for Human GenomicsMiller School of MedicineUniversity of MiamiMiamiFloridaUSA
| | - Michael Cuccaro
- Dr. John T MacDonald Foundation Department of Human GeneticsMiller School of MedicineUniversity of MiamiMiamiFloridaUSA
- John P. Hussman Institute for Human GenomicsMiller School of MedicineUniversity of MiamiMiamiFloridaUSA
| | - William K. Scott
- Dr. John T MacDonald Foundation Department of Human GeneticsMiller School of MedicineUniversity of MiamiMiamiFloridaUSA
- John P. Hussman Institute for Human GenomicsMiller School of MedicineUniversity of MiamiMiamiFloridaUSA
| | - Walter Kukull
- Department of EpidemiologyUniversity of WashingtonSeattleWashingtonUSA
| | - Thomas Montine
- Department of PathologyStanford UniversityStanfordCaliforniaUSA
| | - Gary W. Beecham
- Dr. John T MacDonald Foundation Department of Human GeneticsMiller School of MedicineUniversity of MiamiMiamiFloridaUSA
- John P. Hussman Institute for Human GenomicsMiller School of MedicineUniversity of MiamiMiamiFloridaUSA
| |
Collapse
|
26
|
Russo MJ, MacLeod K, Lamoureux J, Lebovitz R, Pleshkevich M, Steriade C, Wisniewski T, Frontera JA, Kang UJ. Aggregation-Seeding Forms of α-Synuclein Are Not Detected in Acute Coronavirus Disease 2019 Cerebrospinal Fluid. Mov Disord 2022; 37:2462-2463. [PMID: 36208476 PMCID: PMC9874726 DOI: 10.1002/mds.29240] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2022] [Accepted: 09/16/2022] [Indexed: 01/28/2023] Open
Affiliation(s)
- Marco J. Russo
- The Marlene and Paolo Fresco Institute for Parkinson's & Movement Disorders, Departments of Neurology and Neuroscience and Physiology, Neuroscience Institute, The Parekh Center for Interdisciplinary NeurologyNYU Grossman School of MedicineNew YorkNew YorkUSA
- Department of NeurologyNew York University Grossman School of MedicineNew YorkNew YorkUSA
| | | | | | | | - Maria Pleshkevich
- Department of NeurologyNew York University Grossman School of MedicineNew YorkNew YorkUSA
- NYU Comprehensive Epilepsy CenterNew York UniversityNew YorkNew YorkUSA
| | - Claude Steriade
- Department of NeurologyNew York University Grossman School of MedicineNew YorkNew YorkUSA
- NYU Comprehensive Epilepsy CenterNew York UniversityNew YorkNew YorkUSA
| | - Thomas Wisniewski
- Department of NeurologyNew York University Grossman School of MedicineNew YorkNew YorkUSA
- Departments of Neurology, Pathology, and Psychiatry, Center for Cognitive NeurologyNYU Langone Medical CenterNew YorkNew YorkUSA
| | - Jennifer A. Frontera
- Department of NeurologyNew York University Grossman School of MedicineNew YorkNew YorkUSA
| | - Un Jung Kang
- The Marlene and Paolo Fresco Institute for Parkinson's & Movement Disorders, Departments of Neurology and Neuroscience and Physiology, Neuroscience Institute, The Parekh Center for Interdisciplinary NeurologyNYU Grossman School of MedicineNew YorkNew YorkUSA
- Department of NeurologyNew York University Grossman School of MedicineNew YorkNew YorkUSA
| |
Collapse
|
27
|
Bharthur Sanjay A, Patania A, Yan X, Svaldi D, Duran T, Shah N, Nemes S, Chen E, Apostolova LG. Characterization of gene expression patterns in mild cognitive impairment using a transcriptomics approach and neuroimaging endophenotypes. Alzheimers Dement 2022; 18:2493-2508. [PMID: 35142026 PMCID: PMC10078657 DOI: 10.1002/alz.12587] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2021] [Revised: 12/10/2021] [Accepted: 12/15/2021] [Indexed: 01/31/2023]
Abstract
INTRODUCTION Identification of novel therapeutics and risk assessment in early stages of Alzheimer's disease (AD) is a crucial aspect of addressing this complex disease. We characterized gene-expression patterns at the mild cognitive impairment (MCI) stage to identify critical mRNA measures and gene clusters associated with AD pathogenesis. METHODS We used a transcriptomics approach, integrating magnetic resonance imaging (MRI) and peripheral blood-based gene expression data using persistent homology (PH) followed by kernel-based clustering. RESULTS We identified three clusters of genes significantly associated with diagnosis of amnestic MCI. The biological processes associated with each cluster were mitochondrial function, NF-kB signaling, and apoptosis. Cluster-level associations with cortical thickness displayed canonical AD-like patterns. Driver genes from clusters were also validated in an external dataset for prediction of amyloidosis and clinical diagnosis. DISCUSSION We found a disease-relevant transcriptomic signature sensitive to prodromal AD and identified a subset of potential therapeutic targets associated with AD pathogenesis.
Collapse
Affiliation(s)
| | - Alice Patania
- Indiana University Network Sciences InstituteIndiana UniversityBloomingtonIndianaUSA
| | - Xiaoran Yan
- Indiana University Network Sciences InstituteIndiana UniversityBloomingtonIndianaUSA
| | - Diana Svaldi
- Department of NeurologyIndiana University School of MedicineIndianapolisIndianaUSA
| | - Tugce Duran
- Department of Internal Medicine, Section of Gerontology & Geriatric MedicineWake Forest School of MedicineWinston‐SalemNorth CarolinaUSA
| | - Niraj Shah
- Department of NeurologyIndiana University School of MedicineIndianapolisIndianaUSA
| | - Sara Nemes
- Department of NeurologyIndiana University School of MedicineIndianapolisIndianaUSA
| | - Eric Chen
- Department of NeurologyIndiana University School of MedicineIndianapolisIndianaUSA
| | - Liana G. Apostolova
- Department of NeurologyIndiana University School of MedicineIndianapolisIndianaUSA
| |
Collapse
|
28
|
Wang T, Huynh K, Giles C, Mellett NA, Duong T, Nguyen A, Lim WLF, Smith AAT, Olshansky G, Cadby G, Hung J, Hui J, Beilby J, Watts GF, Chatterjee P, Martins I, Laws SM, Bush AI, Rowe CC, Villemagne VL, Ames D, Masters CL, Taddei K, Doré V, Fripp J, Arnold M, Kastenmüller G, Nho K, Saykin AJ, Baillie R, Han X, Martins RN, Moses EK, Kaddurah‐Daouk R, Meikle PJ. APOE ε2 resilience for Alzheimer's disease is mediated by plasma lipid species: Analysis of three independent cohort studies. Alzheimers Dement 2022; 18:2151-2166. [PMID: 35077012 PMCID: PMC9787288 DOI: 10.1002/alz.12538] [Citation(s) in RCA: 8] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/19/2021] [Revised: 10/19/2021] [Accepted: 10/25/2021] [Indexed: 01/31/2023]
Abstract
INTRODUCTION The apolipoprotein E (APOE) genotype is the strongest genetic risk factor for late-onset Alzheimer's disease. However, its effect on lipid metabolic pathways, and their mediating effect on disease risk, is poorly understood. METHODS We performed lipidomic analysis on three independent cohorts (the Australian Imaging, Biomarkers and Lifestyle [AIBL] flagship study, n = 1087; the Alzheimer's Disease Neuroimaging Initiative [ADNI] 1 study, n = 819; and the Busselton Health Study [BHS], n = 4384), and we defined associations between APOE ε2 and ε4 and 569 plasma/serum lipid species. Mediation analysis defined the proportion of the treatment effect of the APOE genotype mediated by plasma/serum lipid species. RESULTS A total of 237 and 104 lipid species were associated with APOE ε2 and ε4, respectively. Of these 68 (ε2) and 24 (ε4) were associated with prevalent Alzheimer's disease. Individual lipid species or lipidomic models of APOE genotypes mediated up to 30% and 10% of APOE ε2 and ε4 treatment effect, respectively. DISCUSSION Plasma lipid species mediate the treatment effect of APOE genotypes on Alzheimer's disease and as such represent a potential therapeutic target.
Collapse
|
29
|
Jun GR, You Y, Zhu C, Meng G, Chung J, Panitch R, Hu J, Xia W, Bennett DA, Foroud TM, Wang L, Haines JL, Mayeux R, Pericak‐Vance MA, Schellenberg GD, Au R, Lunetta KL, Ikezu T, Stein TD, Farrer LA. Protein phosphatase 2A and complement component 4 are linked to the protective effect of APOE ɛ2 for Alzheimer's disease. Alzheimers Dement 2022; 18:2042-2054. [PMID: 35142023 PMCID: PMC9360190 DOI: 10.1002/alz.12607] [Citation(s) in RCA: 9] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2021] [Revised: 12/27/2021] [Accepted: 01/01/2022] [Indexed: 01/31/2023]
Abstract
INTRODUCTION The apolipoprotein E (APOE) ɛ2 allele reduces risk against Alzheimer's disease (AD) but mechanisms underlying this effect are largely unknown. METHODS We conducted a genome-wide association study for AD among 2096 ɛ2 carriers. The potential role of the top-ranked gene and complement 4 (C4) proteins, which were previously linked to AD in ɛ2 carriers, was investigated using human isogenic APOE allele-specific induced pluripotent stem cell (iPSC)-derived neurons and astrocytes and in 224 neuropathologically examined human brains. RESULTS PPP2CB rs117296832 was the second most significantly associated single nucleotide polymorphism among ɛ2 carriers (P = 1.1 × 10-7 ) and the AD risk allele increased PPP2CB expression in blood (P = 6.6 × 10-27 ). PPP2CB expression was correlated with phosphorylated tau231/total tau ratio (P = .01) and expression of C4 protein subunits C4A/B (P = 2.0 × 10-4 ) in the iPSCs. PPP2CB (subunit of protein phosphatase 2A) and C4b protein levels were correlated in brain (P = 3.3 × 10-7 ). DISCUSSION PP2A may be linked to classical complement activation leading to AD-related tau pathology.
Collapse
Affiliation(s)
- Gyungah R. Jun
- Department of Medicine (Biomedical Genetics), Boston University School of MedicineBostonMassachusettsUSA
- Department of Ophthalmology, Boston University School of MedicineBostonMassachusettsUSA
- Department of BiostatisticsBoston University School of Public HealthBostonMassachusettsUSA
| | - Yang You
- Department of Pharmacology & Experimental TherapeuticsBoston University School of MedicineBostonMassachusettsUSA
| | - Congcong Zhu
- Department of Medicine (Biomedical Genetics), Boston University School of MedicineBostonMassachusettsUSA
| | - Gaoyuan Meng
- Department of Veterans Affairs Medical CenterBedfordMassachusettsUSA
| | - Jaeyoon Chung
- Department of Medicine (Biomedical Genetics), Boston University School of MedicineBostonMassachusettsUSA
| | - Rebecca Panitch
- Department of Medicine (Biomedical Genetics), Boston University School of MedicineBostonMassachusettsUSA
| | - Junming Hu
- Department of Medicine (Biomedical Genetics), Boston University School of MedicineBostonMassachusettsUSA
| | - Weiming Xia
- Department of Pharmacology & Experimental TherapeuticsBoston University School of MedicineBostonMassachusettsUSA
- Department of Veterans Affairs Medical CenterBedfordMassachusettsUSA
| | | | - David A. Bennett
- Rush Alzheimer's Disease CenterRush University Medical CenterChicagoIllinoisUSA
| | - Tatiana M. Foroud
- Department of Medical and Molecular GeneticsIndiana UniversityIndianapolisIndianaUSA
| | - Li‐San Wang
- Penn Neurodegeneration Genomics Center, Department of Pathology and Laboratory MedicineUniversity of PennsylvaniaPhiladelphiaPennsylvaniaUSA
| | - Jonathan L. Haines
- Department of Population & Quantitative Health SciencesCase Western Reserve UniversityClevelandOhioUSA
| | - Richard Mayeux
- Taub Institute on Alzheimer's Disease and the Aging Brain, Gertrude H. Sergievsky Center Department of NeurologyColumbia UniversityNew YorkNew YorkUSA
| | - Margaret A. Pericak‐Vance
- John P. Hussman Institute for Human Genomics, Department of Human Genetics, and Dr. John T. Macdonald FoundationUniversity of MiamiMiamiFloridaUSA
| | - Gerard D. Schellenberg
- Penn Neurodegeneration Genomics Center, Department of Pathology and Laboratory MedicineUniversity of PennsylvaniaPhiladelphiaPennsylvaniaUSA
| | - Rhoda Au
- Department of Neurology, Boston University School of MedicineBostonMassachusettsUSA
- Department of Anatomy & Neurobiology, Boston University School of MedicineBostonMassachusettsUSA
- Department of EpidemiologyBoston University School of Public HealthBostonMassachusettsUSA
| | - Kathryn L. Lunetta
- Department of BiostatisticsBoston University School of Public HealthBostonMassachusettsUSA
| | - Tsuneya Ikezu
- Department of Pharmacology & Experimental TherapeuticsBoston University School of MedicineBostonMassachusettsUSA
- Department of Neurology, Boston University School of MedicineBostonMassachusettsUSA
- Center for Systems NeuroscienceBoston University School of MedicineBostonMassachusettsUSA
| | - Thor D. Stein
- Department of Veterans Affairs Medical CenterBedfordMassachusettsUSA
- Department of Pathology & Laboratory Medicine, Boston University School of MedicineBostonMassachusettsUSA
| | - Lindsay A. Farrer
- Department of Medicine (Biomedical Genetics), Boston University School of MedicineBostonMassachusettsUSA
- Department of Ophthalmology, Boston University School of MedicineBostonMassachusettsUSA
- Department of BiostatisticsBoston University School of Public HealthBostonMassachusettsUSA
- Department of Neurology, Boston University School of MedicineBostonMassachusettsUSA
- Department of EpidemiologyBoston University School of Public HealthBostonMassachusettsUSA
| |
Collapse
|
30
|
Bickle J, De Sousa AF, Silva AJ. New research tools suggest a “levels-less” image of the behaving organism and dissolution of the reduction vs. anti-reduction dispute. Front Psychol 2022; 13:990316. [PMID: 36110269 PMCID: PMC9470241 DOI: 10.3389/fpsyg.2022.990316] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/09/2022] [Accepted: 08/05/2022] [Indexed: 11/13/2022] Open
Abstract
A kind of “ruthless reductionism” characterized the experimental practices of the first two decades of molecular and cellular cognition (MCC). More recently, new research tools have expanded experimental practices in this field, enabling researchers to image and manipulate individual molecular mechanisms in behaving organisms with an unprecedented temporal, sub-cellular, cellular, and even circuit-wide specificity. These tools dramatically expand the range and reach of experiments in MCC, and in doing so they may help us transcend the worn-out and counterproductive debates about “reductionism” and “emergence” that divide neuroscientists and philosophers alike. We describe examples of these new tools and illustrate their practical power by presenting an exemplary recent case of MCC research using them. From these tools and results, we provide an initial sketch of a new image of the behaving organism in its full causal-interactive complexity, with its molecules, cells, and circuits combined within the single system that it is. This new image stands in opposition to the traditional “levels” image of the behaving organism, and even the initial sketch we provide of it here offers hope for avoiding the dreary metaphysical debates about “emergence” and “downward causation,” and even the reduction vs. anti-reduction dispute, all dependent upon the familiar “levels” image.
Collapse
Affiliation(s)
- John Bickle
- Department of Philosophy and Religion, Shackouls Honors College, Mississippi State University, Starkville, MS, United States
- Department of Advanced Biomedical Education, University of Mississippi Medical Center, Jackson, MS, United States
- *Correspondence: John Bickle,
| | - André F. De Sousa
- Department of Neurobiology, University of California, Los Angeles, Los Angeles, CA, United States
| | - Alcino J. Silva
- Department of Neurobiology, University of California, Los Angeles, Los Angeles, CA, United States
- Department of Psychiatry and Integrative Center for Learning and Memory, UCLA, Los Angeles, CA, United States
- Department of Psychology and Integrative Center for Learning and Memory, UCLA, Los Angeles, CA, United States
| |
Collapse
|
31
|
Barajas MB, Wang A, Griffiths KK, Sun L, Yang G, Levy RJ. Modeling propofol-induced cardiotoxicity in the isolated-perfused newborn mouse heart. Physiol Rep 2022; 10:e15402. [PMID: 35923108 PMCID: PMC9350423 DOI: 10.14814/phy2.15402] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/14/2022] [Revised: 06/24/2022] [Accepted: 07/11/2022] [Indexed: 06/15/2023] Open
Abstract
Infants and children are vulnerable to developing propofol infusion syndrome (PRIS) and young age is a risk factor. Cardiac involvement is often prominent and associated with death. However, the mechanisms of pediatric PRIS are poorly understood because of the paucity of investigation and lack of a gold standard animal model. Unfortunately, in vivo modeling of PRIS in a newborn mouse is not feasible and would be complicated by confounders. Thus, we focused on propofol-induced cardiotoxicity and aimed to develop an ex-vivo model in the isolated-perfused newborn mouse heart. We hypothesized that the model would recapitulate the key cardiac features of PRIS seen in infants and children and would corroborate prior in vitro observations. Isolated perfused newborn mouse hearts were exposed to a toxic dose of propofol or intralipid for 30-min. Surface electrocardiogram, ventricular contractile force, and oxygen extraction were measured over time. Real-time multiphoton laser imaging was utilized to quantify calcein and tetramethylrhodamine ethyl ester fluorescence. Propidium iodide uptake was assessed following drug exposure. A toxic dose of propofol rapidly induced dysrhythmias, depressed ventricular contractile function, impaired the mitochondrial membrane potential, and increased open probability of the permeability transition pore in propofol-exposed hearts without causing cell death. These features mimicked the hallmarks of pediatric PRIS and corroborated prior observations made in isolated newborn cardiomyocyte mitochondria. Thus, acute propofol-induced cardiotoxicity in the isolated-perfused developing mouse heart may serve as a relevant ex-vivo model for pediatric PRIS.
Collapse
Affiliation(s)
- Matthew B. Barajas
- Department of AnesthesiologyColumbia University Medical CenterNew YorkNew YorkUSA
| | - Aili Wang
- Department of AnesthesiologyColumbia University Medical CenterNew YorkNew YorkUSA
| | - Keren K. Griffiths
- Department of AnesthesiologyColumbia University Medical CenterNew YorkNew YorkUSA
| | - Linlin Sun
- Department of AnesthesiologyColumbia University Medical CenterNew YorkNew YorkUSA
| | - Guang Yang
- Department of AnesthesiologyColumbia University Medical CenterNew YorkNew YorkUSA
| | - Richard J. Levy
- Department of AnesthesiologyColumbia University Medical CenterNew YorkNew YorkUSA
| |
Collapse
|
32
|
Li X, McPherson M, Hager M, Fang Y, Bartke A, Miller RA. Transient early life growth hormone exposure permanently alters brain, muscle, liver, macrophage, and adipocyte status in long-lived Ames dwarf mice. FASEB J 2022; 36:e22394. [PMID: 35704312 PMCID: PMC9250136 DOI: 10.1096/fj.202200143r] [Citation(s) in RCA: 10] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2022] [Revised: 05/18/2022] [Accepted: 05/23/2022] [Indexed: 01/24/2023]
Abstract
The exceptional longevity of Ames dwarf (DF) mice can be abrogated by a brief course of growth hormone (GH) injections started at 2 weeks of age. This transient GH exposure also prevents the increase in cellular stress resistance and decline in hypothalamic inflammation characteristic of DF mice. Here, we show that transient early-life GH treatment leads to permanent alteration of pertinent changes in adipocytes, fat-associated macrophages, liver, muscle, and brain that are seen in DF mice. Ames DF mice, like Snell dwarf and GHRKO mice, show elevation of glycosylphosphatidylinositol specific phospholipase D1 in liver, neurogenesis in brain as indicated by BDNF and DCX proteins, muscle production of fibronectin type III domain-containing protein 5 (a precursor of irisin), uncoupling protein 1 as an index of thermogenic capacity in brown and white fat, and increase in fat-associated anti-inflammatory macrophages. In each case, transient exposure to GH early in life reverts the DF mice to the levels of each protein seen in littermate control animals, in animals evaluated at 15-18 months of age. Thus, many of the traits seen in long-lived mutant mice, pertinent to age-related changes in inflammation, neurogenesis, and metabolic control, are permanently set by early-life GH levels.
Collapse
Affiliation(s)
- Xinna Li
- Department of PathologyUniversity of Michigan School of MedicineAnn ArborMichiganUSA
| | - Madaline McPherson
- College of Literature, Sciences, & the ArtsUniversity of MichiganAnn ArborMichiganUSA
| | - Mary Hager
- College of Literature, Sciences, & the ArtsUniversity of MichiganAnn ArborMichiganUSA
| | - Yimin Fang
- Department of Internal MedicineSouthern Illinois University School of MedicineSpringfieldIllinoisUSA
| | - Andrzej Bartke
- Department of Internal MedicineSouthern Illinois University School of MedicineSpringfieldIllinoisUSA
| | - Richard A. Miller
- Department of PathologyUniversity of Michigan School of MedicineAnn ArborMichiganUSA
- University of Michigan Geriatrics CenterAnn ArborMichiganUSA
| |
Collapse
|
33
|
Cummings J, Lee G, Nahed P, Kambar MEZN, Zhong K, Fonseca J, Taghva K. Alzheimer's disease drug development pipeline: 2022. Alzheimers Dement (N Y) 2022; 8:e12295. [PMID: 35516416 PMCID: PMC9066743 DOI: 10.1002/trc2.12295] [Citation(s) in RCA: 169] [Impact Index Per Article: 84.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 03/15/2022] [Revised: 03/16/2022] [Accepted: 03/17/2022] [Indexed: 12/30/2022]
Abstract
Introduction Alzheimer's disease (AD) represents a global health crisis. Treatments are needed to prevent, delay the onset, slow the progression, improve cognition, and reduce behavioral disturbances of AD. We review the current clinical trials and drugs in development for the treatment of AD. Methods We searched the governmental website clinicaltrials.gov where are all clinical trials conducted in the United States must be registered. We used artificial intelligence (AI) and machine learning (ML) approaches to ensure comprehensive detection and characterization of trials and drugs in development. We use the Common Alzheimer's Disease Research Ontology (CADRO) to classify drug targets and mechanisms of action of drugs in the pipeline. Results As of January 25, 2022 (index date for this study) there were 143 agents in 172 clinical trials for AD. The pipeline included 31 agents in 47 trials in Phase 3, 82 agents in 94 trials in Phase 2, and 30 agents in 31 trials in Phase 1. Disease-modifying therapies represent 83.2% of the total number of agents in trials; symptomatic cognitive enhancing treatments represent 9.8% of agents in trials; and drugs for the treatment of neuropsychiatric symptoms comprise 6.9%. There is a diverse array of drug targets represented by agents in trials including nearly all CADRO categories. Thirty-seven percent of the candidate agents in the pipeline are repurposed drugs approved for other indications. A total of 50,575 participants are needed to fulfill recruitment requirements for all currently active clinical trials. Discussion The AD drug development pipeline has agents representing a substantial array of treatment mechanisms and targets. Advances in drug design, outcome measures, use of biomarkers, and trial conduct promise to accelerate the delivery of new and better treatments for patients with AD. Highlights There are 143 drugs in the current Alzheimer's disease (AD) drug development pipeline.Disease-modifying therapies represent 83.2% of the candidate treatments.Current trials require 50,575 participants who will donate 3,878,843 participant-weeks to clinical trials.The biopharmaceutical industry sponsors 50% of all clinical trials including 68% of Phase 3 trials.Sixty-three percent of Phase 3 trials and 46% of Phase 2 trials include non-North American clinical trial site locations indicating the global ecosystem required for AD drug development.
Collapse
Affiliation(s)
- Jeffrey Cummings
- Chambers‐Grundy Center for Transformative Neuroscience, Department of Brain Health, School of Integrated Health SciencesUniversity of Nevada, Las Vegas (UNLV)HendersonNevadaUSA
- Department of Brain Health, School of Integrated Health SciencesUniversity of Nevada, Las Vegas (UNLV)HendersonNevadaUSA
| | | | - Pouyan Nahed
- Howard R. Hughes College of EngineeringDepartment of Computer ScienceUniversity of Nevada, Las Vegas (UNLV)HendersonNevadaUSA
| | - Mina Esmail Zadeh Nojoo Kambar
- Howard R. Hughes College of EngineeringDepartment of Computer ScienceUniversity of Nevada, Las Vegas (UNLV)HendersonNevadaUSA
| | - Kate Zhong
- Chambers‐Grundy Center for Transformative Neuroscience, Department of Brain Health, School of Integrated Health SciencesUniversity of Nevada, Las Vegas (UNLV)HendersonNevadaUSA
- Department of Brain Health, School of Integrated Health SciencesUniversity of Nevada, Las Vegas (UNLV)HendersonNevadaUSA
| | - Jorge Fonseca
- Howard R. Hughes College of EngineeringDepartment of Computer ScienceUniversity of Nevada, Las Vegas (UNLV)HendersonNevadaUSA
| | - Kazem Taghva
- Howard R. Hughes College of EngineeringDepartment of Computer ScienceUniversity of Nevada, Las Vegas (UNLV)HendersonNevadaUSA
| |
Collapse
|
34
|
Ramos‐Cejudo J, Johnson AD, Beiser A, Seshadri S, Salinas J, Berger JS, Fillmore NR, Do N, Zheng C, Kovbasyuk Z, Ardekani BA, Pomara N, Bubu OM, Parekh A, Convit A, Betensky RA, Wisniewski TM, Osorio RS. Platelet Function Is Associated With Dementia Risk in the Framingham Heart Study. J Am Heart Assoc 2022; 11:e023918. [PMID: 35470685 PMCID: PMC9238609 DOI: 10.1161/jaha.121.023918] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/09/2021] [Accepted: 02/01/2022] [Indexed: 12/15/2022]
Abstract
Background Vascular function is compromised in Alzheimer disease (AD) years before amyloid and tau pathology are detected and a substantial body of work shows abnormal platelet activation states in patients with AD. The aim of our study was to investigate whether platelet function in middle age is independently associated with future risk of AD. Methods and Results We examined associations of baseline platelet function with incident dementia risk in the community-based FHS (Framingham Heart Study) longitudinal cohorts. The association between platelet function and risk of dementia was evaluated using the cumulative incidence function and inverse probability weighted Cox proportional cause-specific hazards regression models, with adjustment for demographic and clinical covariates. Platelet aggregation response was measured by light transmission aggregometry. The final study sample included 1847 FHS participants (average age, 53.0 years; 57.5% women). During follow-up (median, 20.5 years), we observed 154 cases of incident dementia, of which 121 were AD cases. Results from weighted models indicated that platelet aggregation response to adenosine diphosphate 1.0 µmol/L was independently and positively associated with dementia risk, and it was preceded in importance only by age and hypertension. Sensitivity analyses showed associations with the same directionality for participants defined as adenosine diphosphate hyper-responders, as well as the platelet response to 0.1 µmol/L epinephrine. Conclusions Our study shows individuals free of antiplatelet therapy with a higher platelet response are at higher risk of dementia in late life during a 20-year follow-up, reinforcing the role of platelet function in AD risk. This suggests that platelet phenotypes may be associated with the rate of dementia and potentially have prognostic value.
Collapse
Affiliation(s)
- Jaime Ramos‐Cejudo
- Department of PsychiatryNew York University (NYU) Grossman School of MedicineNew YorkNY
- VA Boston Cooperative Studies ProgramMAVERICVA Boston Healthcare SystemBostonMA
| | - Andrew D. Johnson
- Population Sciences BranchDivision of Intramural ResearchNational Heart, Lung, and Blood InstituteFraminghamMA
- The Framingham StudyBostonMA
| | - Alexa Beiser
- The Framingham StudyBostonMA
- Department of BiostatisticsBoston University School of Public HealthBostonMA
- Department of NeurologyBoston University School of MedicineBostonMA
| | - Sudha Seshadri
- The Framingham StudyBostonMA
- Department of NeurologyBoston University School of MedicineBostonMA
- Glenn Biggs Institute for Alzheimer’s and Neurodegenerative DiseasesUniversity of Texas Health Sciences CenterSan AntonioTX
| | - Joel Salinas
- The Framingham StudyBostonMA
- Department of NeurologyCenter for Cognitive NeurologyNYU Grossman School of MedicineNew YorkNY
| | - Jeffrey S. Berger
- Division of Vascular SurgeryDepartment of SurgeryNYU Grossman School of MedicineNew YorkNY
- Divisions of Cardiology and HematologyDepartment MedicineNYU Grossman School of MedicineNew YorkNY
- Center for the Prevention of Cardiovascular DiseaseNYU Grossman School of MedicineNew YorkNY
| | - Nathanael R. Fillmore
- VA Boston Cooperative Studies ProgramMAVERICVA Boston Healthcare SystemBostonMA
- Harvard Medical SchoolBostonMA
| | - Nhan Do
- VA Boston Cooperative Studies ProgramMAVERICVA Boston Healthcare SystemBostonMA
- Boston University School of MedicineBostonMA
| | - Chunlei Zheng
- VA Boston Cooperative Studies ProgramMAVERICVA Boston Healthcare SystemBostonMA
- Boston University School of MedicineBostonMA
| | - Zanetta Kovbasyuk
- Department of PsychiatryNew York University (NYU) Grossman School of MedicineNew YorkNY
| | - Babak A. Ardekani
- Department of PsychiatryNew York University (NYU) Grossman School of MedicineNew YorkNY
- Nathan Kline InstituteOrangeburgNY
| | - Nunzio Pomara
- Department of PsychiatryNew York University (NYU) Grossman School of MedicineNew YorkNY
- Nathan Kline InstituteOrangeburgNY
| | - Omonigho M. Bubu
- Department of PsychiatryNew York University (NYU) Grossman School of MedicineNew YorkNY
| | - Ankit Parekh
- Division of PulmonaryCritical Care, and Sleep MedicineIcahn School of Medicine at Mount SinaiNew YorkNY
| | - Antonio Convit
- Department of PsychiatryNew York University (NYU) Grossman School of MedicineNew YorkNY
- Nathan Kline InstituteOrangeburgNY
| | - Rebecca A. Betensky
- Department of BiostatisticsNew York University School of Global Public HealthNew YorkNY
| | - Thomas M. Wisniewski
- Department of PsychiatryNew York University (NYU) Grossman School of MedicineNew YorkNY
- Department of NeurologyCenter for Cognitive NeurologyNYU Grossman School of MedicineNew YorkNY
- Department of PathologyNYU Grossman School of MedicineNew YorkNY
| | - Ricardo S. Osorio
- Department of PsychiatryNew York University (NYU) Grossman School of MedicineNew YorkNY
- Nathan Kline InstituteOrangeburgNY
| |
Collapse
|
35
|
Bucholc M, Bauermeister S, Kaur D, McClean PL, Todd S. The impact of hearing impairment and hearing aid use on progression to mild cognitive impairment in cognitively healthy adults: An observational cohort study. Alzheimers Dement (N Y) 2022; 8:e12248. [PMID: 35229022 PMCID: PMC8863441 DOI: 10.1002/trc2.12248] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 05/10/2021] [Revised: 11/25/2021] [Accepted: 12/15/2021] [Indexed: 11/23/2022]
Abstract
INTRODUCTION We assessed the association of self-reported hearing impairment and hearing aid use with cognitive decline and progression to mild cognitive impairment (MCI). METHODS We used a large referral-based cohort of 4358 participants obtained from the National Alzheimer's Coordinating Center. The standard covariate-adjusted Cox proportional hazards model, the marginal structural Cox model with inverse probability weighting, standardized Kaplan-Meier curves, and linear mixed-effects models were applied to test the hypotheses. RESULTS Hearing impairment was associated with increased risk of MCI (standardized hazard ratio [HR] 2.58, 95% confidence interval [CI: 1.73 to 3.84], P = .004) and an accelerated rate of cognitive decline (P < .001). Hearing aid users were less likely to develop MCI than hearing-impaired individuals who did not use a hearing aid (HR 0.47, 95% CI [0.29 to 0.74], P = .001). No difference in risk of MCI was observed between individuals with normal hearing and hearing-impaired adults using hearing aids (HR 0.86, 95% CI [0.56 to 1.34], P = .51). DISCUSSION Use of hearing aids may help mitigate cognitive decline associated with hearing loss.
Collapse
Affiliation(s)
- Magda Bucholc
- Cognitive Analytics Research LabSchool of ComputingEngineering & Intelligent SystemsUlster UniversityLondonderryUK
| | | | - Daman Kaur
- Northern Ireland Centre for Stratified MedicineBiomedical Sciences Research InstituteUlster UniversityLondonderryUK
| | - Paula L. McClean
- Northern Ireland Centre for Stratified MedicineBiomedical Sciences Research InstituteUlster UniversityLondonderryUK
| | - Stephen Todd
- Altnagelvin Area HospitalWestern Health and Social Care TrustLondonderryUK
| |
Collapse
|
36
|
Zhang X, Farrell JJ, Tong T, Hu J, Zhu C, Wang L, Mayeux R, Haines JL, Pericak‐Vance MA, Schellenberg GD, Lunetta KL, Farrer LA. Association of mitochondrial variants and haplogroups identified by whole exome sequencing with Alzheimer's disease. Alzheimers Dement 2022; 18:294-306. [PMID: 34152079 PMCID: PMC8764625 DOI: 10.1002/alz.12396] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2020] [Revised: 05/03/2021] [Accepted: 05/04/2021] [Indexed: 12/30/2022]
Abstract
INTRODUCTION Findings regarding the association between mitochondrial DNA (mtDNA) variants and Alzheimer's disease (AD) are inconsistent. METHODS We developed a pipeline for accurate assembly and variant calling in mitochondrial genomes embedded within whole exome sequences (WES) from 10,831 participants from the Alzheimer's Disease Sequencing Project (ADSP). Association of AD risk was evaluated with each mtDNA variant and variants located in 1158 nuclear genes related to mitochondrial function using the SCORE test. Gene-based tests were performed using SKAT-O. RESULTS Analysis of 4220 mtDNA variants revealed study-wide significant association of AD with a rare MT-ND4L variant (rs28709356 C>T; minor allele frequency = 0.002; P = 7.3 × 10-5 ) as well as with MT-ND4L in a gene-based test (P = 6.71 × 10-5 ). Significant association was also observed with a MT-related nuclear gene, TAMM41, in a gene-based test (P = 2.7 × 10-5 ). The expression of TAMM41 was lower in AD cases than controls (P = .00046) or mild cognitive impairment cases (P = .03). DISCUSSION Significant findings in MT-ND4L and TAMM41 provide evidence for a role of mitochondria in AD.
Collapse
Affiliation(s)
- Xiaoling Zhang
- Department of Medicine (Biomedical Genetics)Boston University School of Medicine72 East Concord StreetBostonMassachusetts02118USA
- Department of BiostatisticsBoston University School of Public Health801 Massachusetts Avenue 3rd FloorBostonMassachusetts02118USA
| | - John J. Farrell
- Department of Medicine (Biomedical Genetics)Boston University School of Medicine72 East Concord StreetBostonMassachusetts02118USA
| | - Tong Tong
- Department of Medicine (Biomedical Genetics)Boston University School of Medicine72 East Concord StreetBostonMassachusetts02118USA
| | - Junming Hu
- Department of Medicine (Biomedical Genetics)Boston University School of Medicine72 East Concord StreetBostonMassachusetts02118USA
| | - Congcong Zhu
- Department of Medicine (Biomedical Genetics)Boston University School of Medicine72 East Concord StreetBostonMassachusetts02118USA
| | | | - Li‐San Wang
- Department of Pathology and Laboratory MedicineUniversity of Pennsylvania Perelman School of MedicinePhiladelphiaPennsylvania19104USA
| | - Richard Mayeux
- Department of NeurologyColumbia UniversityNew YorkNew York10032USA
| | - Jonathan L. Haines
- Department of Population and Quantitative Health Sciences Case Western Reserve UniversityClevelandOhio44106USA
| | | | - Gerard D. Schellenberg
- Department of Pathology and Laboratory MedicineUniversity of Pennsylvania Perelman School of MedicinePhiladelphiaPennsylvania19104USA
| | - Kathryn L. Lunetta
- Department of BiostatisticsBoston University School of Public Health801 Massachusetts Avenue 3rd FloorBostonMassachusetts02118USA
| | - Lindsay A. Farrer
- Department of Medicine (Biomedical Genetics)Boston University School of Medicine72 East Concord StreetBostonMassachusetts02118USA
- Department of BiostatisticsBoston University School of Public Health801 Massachusetts Avenue 3rd FloorBostonMassachusetts02118USA
- Department of NeurologyBoston University School of MedicineBostonMassachusetts02118USA
- Department of OphthalmologyBoston University School of MedicineBostonMassachusetts02118USA
- Department of EpidemiologyBoston University School of Public Health715 Albany StreetBostonMassachusetts02118USA
| |
Collapse
|
37
|
Wierenga LM, Doucet GE, Dima D, Agartz I, Aghajani M, Akudjedu TN, Albajes‐Eizagirre A, Alnæs D, Alpert KI, Andreassen OA, Anticevic A, Asherson P, Banaschewski T, Bargallo N, Baumeister S, Baur‐Streubel R, Bertolino A, Bonvino A, Boomsma DI, Borgwardt S, Bourque J, den Braber A, Brandeis D, Breier A, Brodaty H, Brouwer RM, Buitelaar JK, Busatto GF, Calhoun VD, Canales‐Rodríguez EJ, Cannon DM, Caseras X, Castellanos FX, Chaim‐Avancini TM, Ching CRK, Clark VP, Conrod PJ, Conzelmann A, Crivello F, Davey CG, Dickie EW, Ehrlich S, van't Ent D, Fisher SE, Fouche J, Franke B, Fuentes‐Claramonte P, de Geus EJC, Di Giorgio A, Glahn DC, Gotlib IH, Grabe HJ, Gruber O, Gruner P, Gur RE, Gur RC, Gurholt TP, de Haan L, Haatveit B, Harrison BJ, Hartman CA, Hatton SN, Heslenfeld DJ, van den Heuvel OA, Hickie IB, Hoekstra PJ, Hohmann S, Holmes AJ, Hoogman M, Hosten N, Howells FM, Hulshoff Pol HE, Huyser C, Jahanshad N, James AC, Jiang J, Jönsson EG, Joska JA, Kalnin AJ, Klein M, Koenders L, Kolskår KK, Krämer B, Kuntsi J, Lagopoulos J, Lazaro L, Lebedeva IS, Lee PH, Lochner C, Machielsen MWJ, Maingault S, Martin NG, Martínez‐Zalacaín I, Mataix‐Cols D, Mazoyer B, McDonald BC, McDonald C, McIntosh AM, McMahon KL, McPhilemy G, van der Meer D, Menchón JM, Naaijen J, Nyberg L, Oosterlaan J, Paloyelis Y, Pauli P, Pergola G, Pomarol‐Clotet E, Portella MJ, Radua J, Reif A, Richard G, Roffman JL, Rosa PGP, Sacchet MD, Sachdev PS, Salvador R, Sarró S, Satterthwaite TD, Saykin AJ, Serpa MH, Sim K, Simmons A, Smoller JW, Sommer IE, Soriano‐Mas C, Stein DJ, Strike LT, Szeszko PR, Temmingh HS, Thomopoulos SI, Tomyshev AS, Trollor JN, Uhlmann A, Veer IM, Veltman DJ, Voineskos A, Völzke H, Walter H, Wang L, Wang Y, Weber B, Wen W, West JD, Westlye LT, Whalley HC, Williams SCR, Wittfeld K, Wolf DH, Wright MJ, Yoncheva YN, Zanetti MV, Ziegler GC, de Zubicaray GI, Thompson PM, Crone EA, Frangou S, Tamnes CK. Greater male than female variability in regional brain structure across the lifespan. Hum Brain Mapp 2022; 43:470-499. [PMID: 33044802 PMCID: PMC8675415 DOI: 10.1002/hbm.25204] [Citation(s) in RCA: 42] [Impact Index Per Article: 21.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/04/2020] [Revised: 08/10/2020] [Accepted: 09/05/2020] [Indexed: 12/25/2022] Open
Abstract
For many traits, males show greater variability than females, with possible implications for understanding sex differences in health and disease. Here, the ENIGMA (Enhancing Neuro Imaging Genetics through Meta-Analysis) Consortium presents the largest-ever mega-analysis of sex differences in variability of brain structure, based on international data spanning nine decades of life. Subcortical volumes, cortical surface area and cortical thickness were assessed in MRI data of 16,683 healthy individuals 1-90 years old (47% females). We observed significant patterns of greater male than female between-subject variance for all subcortical volumetric measures, all cortical surface area measures, and 60% of cortical thickness measures. This pattern was stable across the lifespan for 50% of the subcortical structures, 70% of the regional area measures, and nearly all regions for thickness. Our findings that these sex differences are present in childhood implicate early life genetic or gene-environment interaction mechanisms. The findings highlight the importance of individual differences within the sexes, that may underpin sex-specific vulnerability to disorders.
Collapse
Affiliation(s)
- Lara M Wierenga
- Institute of PsychologyLeiden UniversityLeidenThe Netherlands
- Leiden Institute for Brain and CognitionLeidenThe Netherlands
| | - Gaelle E Doucet
- Department of PsychiatryIcahn School of Medicine at Mount SinaiNew YorkNew YorkUSA
- Boys Town National Research HospitalOmahaNebraskaUSA
| | - Danai Dima
- Department of Psychology, School of Arts and Social Sciences, CityUniversity of LondonLondonUK
- Department of Neuroimaging, Institute of Psychiatry, Psychology and NeuroscienceKing's College LondonLondonUK
| | - Ingrid Agartz
- Norwegian Centre for Mental Disorders Research (NORMENT), Division of Mental Health and Addiction, Institute of Clinical MedicineUniversity of OsloOsloNorway
- Department of Psychiatric ResearchDiakonhjemmet HospitalOsloNorway
- Centre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet, & Stockholm Health Care ServicesStockholm County CouncilStockholmSweden
| | - Moji Aghajani
- Department of Psychiatry, Amsterdam Neuroscience, Amsterdam UMCVrije UniversiteitAmsterdamThe Netherlands
- Department of Research & InnovationGGZ inGeestAmsterdamThe Netherlands
- Institute of Education and Child Studies, Forensic Family and Youth CareLeiden UniversityLeidenThe Netherlands
| | - Theophilus N Akudjedu
- Centre for Neuroimaging & Cognitive Genomics (NICOG), Clinical Neuroimaging Laboratory, NCBES Galway Neuroscience Centre, College of Medicine Nursing and Health SciencesNational University of Ireland GalwayGalwayIreland
- Institute of Medical Imaging & Visualisation, Faculty of Health & Social SciencesBournemouth UniversityBournemouthUK
| | - Anton Albajes‐Eizagirre
- FIDMAG Germanes Hospitalàries Research FoundationBarcelonaSpain
- Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM)MadridSpain
- Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)BarcelonaSpain
| | - Dag Alnæs
- Norwegian Centre for Mental Disorders Research (NORMENT), Division of Mental Health and Addiction, Institute of Clinical MedicineUniversity of OsloOsloNorway
- Norwegian Centre for Mental Disorders Research (NORMENT), Division of Mental Health and AddictionOslo University HospitalOsloNorway
| | - Kathryn I Alpert
- Department of Psychiatry and Behavioral SciencesNorthwestern University Feinberg School of MedicineChicagoIllinoisUSA
| | - Ole A Andreassen
- Norwegian Centre for Mental Disorders Research (NORMENT), Division of Mental Health and Addiction, Institute of Clinical MedicineUniversity of OsloOsloNorway
- Norwegian Centre for Mental Disorders Research (NORMENT), Division of Mental Health and AddictionOslo University HospitalOsloNorway
| | - Alan Anticevic
- Department of PsychiatryYale UniversityNew HavenConnecticutUSA
| | - Philip Asherson
- Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and NeuroscienceKing's College LondonLondonUK
| | - Tobias Banaschewski
- Department of Child and Adolescent Psychiatry and Psychotherapy, Central Institute of Mental HealthUniversity of Heidelberg, Medical Faculty MannheimMannheimGermany
| | - Nuria Bargallo
- Imaging Diagnostic CenterHospital ClínicBarcelonaSpain
- Magnetic Resonance Image Core FacilityIDIBAPSBarcelonaSpain
| | - Sarah Baumeister
- Department of Child and Adolescent Psychiatry and Psychotherapy, Central Institute of Mental HealthUniversity of Heidelberg, Medical Faculty MannheimMannheimGermany
| | | | - Alessandro Bertolino
- Department of Basic Medical Science, Neuroscience and Sense OrgansUniversity of Bari Aldo MoroBariItaly
| | - Aurora Bonvino
- Department of Basic Medical Science, Neuroscience and Sense OrgansUniversity of Bari Aldo MoroBariItaly
| | - Dorret I Boomsma
- Department of Biological PsychologyVU University AmsterdamAmsterdamThe Netherlands
| | - Stefan Borgwardt
- Department of PsychiatryUniversity of BaselBaselSwitzerland
- Department of PsychiatryUniversity of LübeckLübeckGermany
| | - Josiane Bourque
- Department of PsychiatryUniversity of PennsylvaniaPhiladelphiaPennsylvaniaUSA
- CHU Sainte‐Justine Research CenterMontrealQuebecCanada
| | - Anouk den Braber
- Department of Biological PsychologyVU University AmsterdamAmsterdamThe Netherlands
- Alzheimer CenterAmsterdam UMC, Location VUMCAmsterdamThe Netherlands
| | - Daniel Brandeis
- Department of Child and Adolescent Psychiatry and Psychotherapy, Central Institute of Mental HealthUniversity of Heidelberg, Medical Faculty MannheimMannheimGermany
- Department of Child and Adolescent Psychiatry and Psychotherapy, Psychiatric HospitalUniversity of ZurichZurichSwitzerland
- Zurich Center for Integrative Human PhysiologyUniversity of ZurichZurichSwitzerland
- Neuroscience Centre ZurichUniversity and ETH ZurichZurichSwitzerland
| | - Alan Breier
- Department of PsychiatryIndiana University School of MedicineIndianapolisIndianaUSA
| | - Henry Brodaty
- Centre for Healthy Brain Ageing, School of PsychiatryUniversity of New South WalesSydneyNew South WalesAustralia
- Dementia Centre for Research Collaboration, School of PsychiatryUniversity of New South WalesSydneyNew South WalesAustralia
| | - Rachel M Brouwer
- Department of Psychiatry, University Medical Center Utrecht Brain CenterUtrecht UniversityUtrechtThe Netherlands
| | - Jan K Buitelaar
- Department of Cognitive NeuroscienceRadboud University Medical CentreNijmegenThe Netherlands
- Karakter Child and Adolescent Psychiatry University CentreNijmegenThe Netherlands
| | - Geraldo F Busatto
- Laboratory of Psychiatric Neuroimaging (LIM‐21), Departamento e Instituto de Psiquiatria, Hospital das Clinicas HCFMUSP, Faculdade de MedicinaUniversidade de São PauloSão PauloBrazil
| | - Vince D Calhoun
- Tri‐institutional Center for Translational Research in Neuroimaging and Data Science (TReNDS)Georgia State, Georgia TechAtlantaGeorgiaUSA
| | - Erick J Canales‐Rodríguez
- FIDMAG Germanes Hospitalàries Research FoundationBarcelonaSpain
- Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM)MadridSpain
| | - Dara M Cannon
- Centre for Neuroimaging & Cognitive Genomics (NICOG), Clinical Neuroimaging Laboratory, NCBES Galway Neuroscience Centre, College of Medicine Nursing and Health SciencesNational University of Ireland GalwayGalwayIreland
| | - Xavier Caseras
- MRC Centre for Neuropsychiatric Genetics and GenomicsCardiff UniversityCardiffUK
| | - Francisco X Castellanos
- Department of Child and Adolescent PsychiatryNYU Grossman School of MedicineNew YorkNew YorkUSA
- Nathan Kline Institute for Psychiatric ResearchOrangeburgNew YorkUSA
| | - Tiffany M Chaim‐Avancini
- Laboratory of Psychiatric Neuroimaging (LIM‐21), Departamento e Instituto de Psiquiatria, Hospital das Clinicas HCFMUSP, Faculdade de MedicinaUniversidade de São PauloSão PauloBrazil
| | - Christopher RK Ching
- Imaging Genetics Center, Mark and Mary Stevens Neuroimaging and Informatics Institute, Keck School of MedicineUniversity of Southern CaliforniaLos AngelesCaliforniaUSA
| | - Vincent P Clark
- Psychology Clinical Neuroscience Center, Department of PsychologyUniversity of New MexicoAlbuquerqueNew MexicoUSA
- Mind Research NetworkAlbuquerqueNew MexicoUSA
| | - Patricia J Conrod
- CHU Sainte‐Justine Research CenterMontrealQuebecCanada
- Department of PsychiatryUniversity of MontrealMontrealCanada
| | - Annette Conzelmann
- Department of Child and Adolescent Psychiatry, Psychosomatics and PsychotherapyUniversity of TübingenTübingenGermany
- Department of Psychology (Clinical Psychology II)PFH – Private University of Applied SciencesGöttingenGermany
| | - Fabrice Crivello
- Groupe d'Imagerie NeurofonctionnelleInstitut des Maladies NeurodégénérativesBordeauxFrance
| | - Christopher G Davey
- Centre for Youth Mental HealthUniversity of MelbourneParkvilleVictoriaAustralia
- OrygenParkvilleVictoriaAustralia
| | - Erin W Dickie
- Campbell Family Mental Health Institute, Centre for Addiction and Mental Health, Department of PsychiatryUniversity of TorontoTorontoCanada
- Department of PsychiatryUniversity of TorontoTorontoOntarioCanada
| | - Stefan Ehrlich
- Division of Psychological & Social Medicine and Developmental Neurosciences; Technische Universität Dresden, Faculty of MedicineUniversity Hospital C.G. CarusDresdenGermany
| | - Dennis van't Ent
- Department of Biological PsychologyVU University AmsterdamAmsterdamThe Netherlands
| | - Simon E Fisher
- Language and Genetics DepartmentMax Planck Institute for PsycholinguisticsNijmegenThe Netherlands
- Donders Institute for Brain, Cognition and BehaviourRadboud UniversityNijmegenThe Netherlands
| | - Jean‐Paul Fouche
- Department of Psychiatry and Neuroscience InstituteUniversity of Cape TownCape TownWestern CapeSouth Africa
| | - Barbara Franke
- Donders Institute for Brain, Cognition and BehaviourRadboud UniversityNijmegenThe Netherlands
- Department of Human GeneticsRadboud University Medical CenterNijmegenThe Netherlands
- Department of PsychiatryRadboud University Medical CenterNijmegenThe Netherlands
| | - Paola Fuentes‐Claramonte
- FIDMAG Germanes Hospitalàries Research FoundationBarcelonaSpain
- Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM)MadridSpain
| | - Eco JC de Geus
- Department of Biological PsychologyVU University AmsterdamAmsterdamThe Netherlands
| | | | - David C Glahn
- Tommy Fuss Center for Neuropsychiatric Disease Research, Department of PsychiatryBoston Children's Hospital and Harvard Medical SchoolBostonMassachusettsUSA
- Olin Center for Neuropsychiatric Research, Institute of LivingHartford HospitalHartfordConnecticutUSA
| | - Ian H Gotlib
- Department of PsychologyStanford UniversityStanfordCaliforniaUSA
| | - Hans J Grabe
- Department of Psychiatry and PsychotherapyUniversity Medicine GreifswaldGreifswaldGermany
- German Center for Neurodegenerative Diseases (DZNE)Site Rostock/GreifswaldGreifswaldGermany
| | - Oliver Gruber
- Section for Experimental Psychopathology and Neuroimaging, Department of General PsychiatryHeidelberg University HospitalHeidelbergGermany
| | - Patricia Gruner
- Department of PsychiatryYale UniversityNew HavenConnecticutUSA
| | - Raquel E Gur
- Department of PsychiatryUniversity of PennsylvaniaPhiladelphiaPennsylvaniaUSA
- Lifespan Brain InstituteChildren's Hospital of PhiladelphiaPhiladelphiaPennsylvaniaUSA
| | - Ruben C Gur
- Department of PsychiatryUniversity of PennsylvaniaPhiladelphiaPennsylvaniaUSA
| | - Tiril P Gurholt
- Norwegian Centre for Mental Disorders Research (NORMENT), Division of Mental Health and Addiction, Institute of Clinical MedicineUniversity of OsloOsloNorway
- Norwegian Centre for Mental Disorders Research (NORMENT), Division of Mental Health and AddictionOslo University HospitalOsloNorway
| | - Lieuwe de Haan
- Department of Early PsychosisAmsterdam UMCAmsterdamThe Netherlands
| | - Beathe Haatveit
- Norwegian Centre for Mental Disorders Research (NORMENT), Division of Mental Health and Addiction, Institute of Clinical MedicineUniversity of OsloOsloNorway
- Norwegian Centre for Mental Disorders Research (NORMENT), Division of Mental Health and AddictionOslo University HospitalOsloNorway
| | - Ben J Harrison
- Melbourne Neuropsychiatry Centre, Department of PsychiatryThe University of Melbourne & Melbourne HealthMelbourneAustralia
| | - Catharina A Hartman
- Interdisciplinary Center Psychopathology and Emotion regulationUniversity of Groningen, University Medical Center GroningenGroningenThe Netherlands
| | - Sean N Hatton
- Brain and Mind CentreUniversity of SydneySydneyNew South WalesAustralia
- Department of NeurosciencesUniversity of California San DiegoLa JollaCaliforniaUSA
| | - Dirk J Heslenfeld
- Departments of Experimental and Clinical PsychologyVrije Universiteit AmsterdamAmsterdamThe Netherlands
| | - Odile A van den Heuvel
- Department of Psychiatry, Amsterdam Neuroscience, Amsterdam UMCVrije UniversiteitAmsterdamThe Netherlands
- Department of Anatomy & Neurosciences, Amsterdam NeuroscienceAmsterdam UMC, Vrije Universiteit AmsterdamAmsterdamThe Netherlands
| | - Ian B Hickie
- Brain and Mind CentreUniversity of SydneySydneyNew South WalesAustralia
| | - Pieter J Hoekstra
- Department of PsychiatryUniversity of Groningen, University Medical Center GroningenGroningenThe Netherlands
| | - Sarah Hohmann
- Department of Child and Adolescent Psychiatry and Psychotherapy, Central Institute of Mental HealthUniversity of Heidelberg, Medical Faculty MannheimMannheimGermany
| | - Avram J Holmes
- Department of PsychiatryYale UniversityNew HavenConnecticutUSA
- Department of PsychologyYale UniversityNew HavenConnecticutUSA
- Department of PsychiatryMassachusetts General HospitalBostonMassachusettsUSA
| | - Martine Hoogman
- Donders Institute for Brain, Cognition and BehaviourRadboud UniversityNijmegenThe Netherlands
- Department of Human GeneticsRadboud University Medical CenterNijmegenThe Netherlands
| | - Norbert Hosten
- Institute of Diagnostic Radiology and NeuroradiologyUniversity Medicine GreifswaldGreifswaldGermany
| | - Fleur M Howells
- Neuroscience InstituteUniversity of Cape TownCape TownWestern CapeSouth Africa
- Department of Psychiatry and Mental HealthUniversity of Cape TownCape TownWestern CapeSouth Africa
| | - Hilleke E Hulshoff Pol
- Department of Psychiatry, University Medical Center Utrecht Brain CenterUtrecht UniversityUtrechtThe Netherlands
| | - Chaim Huyser
- De Bascule, Academic center child and adolescent psychiatryDuivendrechtThe Netherlands
- Amsterdam UMC Department of Child and Adolescent PsychiatryAmsterdamThe Netherlands
| | - Neda Jahanshad
- Imaging Genetics Center, Mark and Mary Stevens Neuroimaging and Informatics Institute, Keck School of MedicineUniversity of Southern CaliforniaLos AngelesCaliforniaUSA
| | - Anthony C James
- Department of PsychiatryWarneford HospitalOxfordUK
- Highfield UnitWarneford HospitalOxfordUK
| | - Jiyang Jiang
- Centre for Healthy Brain Ageing, School of PsychiatryUniversity of New South WalesSydneyNew South WalesAustralia
| | - Erik G Jönsson
- Norwegian Centre for Mental Disorders Research (NORMENT), Division of Mental Health and Addiction, Institute of Clinical MedicineUniversity of OsloOsloNorway
- Centre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet, & Stockholm Health Care ServicesStockholm County CouncilStockholmSweden
| | - John A Joska
- Department of Psychiatry and Mental HealthUniversity of Cape TownCape TownWestern CapeSouth Africa
| | - Andrew J Kalnin
- Department of RadiologyThe Ohio State University College of MedicineColumbusOhioUSA
| | | | - Marieke Klein
- Department of Psychiatry, University Medical Center Utrecht Brain CenterUtrecht UniversityUtrechtThe Netherlands
- Donders Institute for Brain, Cognition and BehaviourRadboud UniversityNijmegenThe Netherlands
- Department of Human GeneticsRadboud University Medical CenterNijmegenThe Netherlands
| | - Laura Koenders
- Department of Early PsychosisAmsterdam UMCAmsterdamThe Netherlands
| | - Knut K Kolskår
- Norwegian Centre for Mental Disorders Research (NORMENT), Division of Mental Health and AddictionOslo University HospitalOsloNorway
- Department of PsychologyUniversity of OsloOsloNorway
- Sunnaas Rehabilitation Hospital HTNesoddenNorway
| | - Bernd Krämer
- Section for Experimental Psychopathology and Neuroimaging, Department of General PsychiatryHeidelberg University HospitalHeidelbergGermany
| | - Jonna Kuntsi
- Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and NeuroscienceKing's College LondonLondonUK
| | - Jim Lagopoulos
- Sunshine Coast Mind and Neuroscience Thompson InstituteBirtinyaQueenslandAustralia
- University of the Sunshine CoastSunshine CoastQueenslandAustralia
| | - Luisa Lazaro
- Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM)MadridSpain
- Department of Child and Adolescent Psychiatry and PsychologyHospital ClínicBarcelonaSpain
- August Pi i Sunyer Biomedical Research Institut (IDIBAPS)BarcelonaSpain
- Department of MedicineUniversity of BarcelonaBarcelonaSpain
| | - Irina S Lebedeva
- Laboratory of Neuroimaging and Multimodal AnalysisMental Health Research CenterMoscowRussia
| | - Phil H Lee
- Department of PsychiatryMassachusetts General HospitalBostonMassachusettsUSA
- Department of PsychiatryHarvard Medical SchoolBostonMassachusettsUSA
| | - Christine Lochner
- SA MRC Unit on Risk and Resilience in Mental Disorders, Department of PsychiatryStellenbosch UniversityCape TownWestern CapeSouth Africa
| | | | - Sophie Maingault
- Institut des maladies neurodégénérativesUniversité de BordeauxBordeauxFrance
| | - Nicholas G Martin
- Genetic EpidemiologyQIMR Berghofer Medical Research InstituteBrisbaneQueenslandAustralia
| | - Ignacio Martínez‐Zalacaín
- Department of Psychiatry, Bellvitge University HospitalBellvitge Biomedical Research Institute‐IDIBELLBarcelonaSpain
- Department of Clinical SciencesUniversity of BarcelonaBarcelonaSpain
| | - David Mataix‐Cols
- Centre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet, & Stockholm Health Care ServicesStockholm County CouncilStockholmSweden
| | - Bernard Mazoyer
- University of BordeauxBordeauxFrance
- Bordeaux University HospitalBordeauxFrance
| | - Brenna C McDonald
- Department of Radiology and Imaging SciencesIndiana University School of MedicineIndianapolisIndianaUSA
| | - Colm McDonald
- Centre for Neuroimaging & Cognitive Genomics (NICOG), Clinical Neuroimaging Laboratory, NCBES Galway Neuroscience Centre, College of Medicine Nursing and Health SciencesNational University of Ireland GalwayGalwayIreland
| | | | - Katie L McMahon
- Herston Imaging Research Facility and School of Clinical SciencesQueensland University of Technology (QUT)BrisbaneQueenslandAustralia
- Faculty of Health, Institute of Health and Biomedical InnovationQueensland University of Technology (QUT)BrisbaneQueenslandAustralia
| | - Genevieve McPhilemy
- Centre for Neuroimaging & Cognitive Genomics (NICOG), Clinical Neuroimaging Laboratory, NCBES Galway Neuroscience Centre, College of Medicine Nursing and Health SciencesNational University of Ireland GalwayGalwayIreland
| | - Dennis van der Meer
- Norwegian Centre for Mental Disorders Research (NORMENT), Division of Mental Health and Addiction, Institute of Clinical MedicineUniversity of OsloOsloNorway
- Norwegian Centre for Mental Disorders Research (NORMENT), Division of Mental Health and AddictionOslo University HospitalOsloNorway
- School of Mental Health and Neuroscience, Faculty of Health, Medicine and Life SciencesMaastricht UniversityMaastrichtThe Netherlands
| | - José M Menchón
- Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM)MadridSpain
- Department of Psychiatry, Bellvitge University HospitalBellvitge Biomedical Research Institute‐IDIBELLBarcelonaSpain
- Department of Clinical SciencesUniversity of BarcelonaBarcelonaSpain
| | - Jilly Naaijen
- Department of Cognitive NeuroscienceRadboud University Medical CentreNijmegenThe Netherlands
| | - Lars Nyberg
- Department of Radiation SciencesUmeå UniversityUmeåSweden
- Department of Integrative Medical BiologyUmeå UniversityUmeåSweden
| | - Jaap Oosterlaan
- Emma Children's Hospital, Amsterdam UMC University of Amsterdam and Vrije Universiteit AmsterdamEmma Neuroscience Group, Department of Pediatrics, Amsterdam Reproduction & DevelopmentAmsterdamThe Netherlands
- Clinical Neuropsychology SectionVrije Universiteit AmsterdamAmsterdamThe Netherlands
| | - Yannis Paloyelis
- Department of Neuroimaging, Institute of Psychiatry, Psychology and NeuroscienceKing's College LondonLondonUK
| | - Paul Pauli
- Department of PsychologyUniversity of WürzburgWürzburgGermany
- Centre of Mental Health, Medical FacultyUniversity of WürzburgWürzburgGermany
| | - Giulio Pergola
- Department of Basic Medical Science, Neuroscience and Sense OrgansUniversity of Bari Aldo MoroBariItaly
- Lieber Institute for Brain DevelopmentJohns Hopkins Medical CampusBaltimoreMary LandUSA
| | - Edith Pomarol‐Clotet
- FIDMAG Germanes Hospitalàries Research FoundationBarcelonaSpain
- Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM)MadridSpain
| | - Maria J Portella
- Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM)MadridSpain
- Department of PsychiatryInstitut d'Investigació Biomèdica Sant PauBarcelonaSpain
| | - Joaquim Radua
- Centre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet, & Stockholm Health Care ServicesStockholm County CouncilStockholmSweden
- FIDMAG Germanes Hospitalàries Research FoundationBarcelonaSpain
- Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM)MadridSpain
- Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)BarcelonaSpain
- Early Psychosis: Interventions and Clinical‐detection (EPIC) lab, Department of Psychosis StudiesInstitute of Psychiatry, Psychology and Neuroscience, King's College LondonLondonUK
| | - Andreas Reif
- Department of Psychiatry, Psychosomatic Medicine and PsychotherapyUniversity Hospital FrankfurtFrankfur am MaintGermany
| | - Geneviève Richard
- Norwegian Centre for Mental Disorders Research (NORMENT), Division of Mental Health and Addiction, Institute of Clinical MedicineUniversity of OsloOsloNorway
- Norwegian Centre for Mental Disorders Research (NORMENT), Division of Mental Health and AddictionOslo University HospitalOsloNorway
| | - Joshua L Roffman
- Department of PsychiatryMassachusetts General Hospital and Harvard Medical SchoolCharlestownMassachusettsUSA
| | - Pedro GP Rosa
- Laboratory of Psychiatric Neuroimaging (LIM‐21), Departamento e Instituto de Psiquiatria, Hospital das Clinicas HCFMUSP, Faculdade de MedicinaUniversidade de São PauloSão PauloBrazil
| | - Matthew D Sacchet
- Center for Depression, Anxiety, and Stress ResearchMcLean Hospital, Harvard Medical SchoolBelmontMassachusettsUSA
| | - Perminder S Sachdev
- Centre for Healthy Brain Ageing, School of PsychiatryUniversity of New South WalesSydneyNew South WalesAustralia
- Neuropsychiatric InstituteThe Prince of Wales HospitalRandwickNew South WalesAustralia
| | - Raymond Salvador
- FIDMAG Germanes Hospitalàries Research FoundationBarcelonaSpain
- Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM)MadridSpain
| | - Salvador Sarró
- FIDMAG Germanes Hospitalàries Research FoundationBarcelonaSpain
- Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM)MadridSpain
| | | | - Andrew J Saykin
- Department of Radiology and Imaging SciencesIndiana University School of MedicineIndianapolisIndianaUSA
- Indiana Alzheimer Disease CenterIndianapolisIndianaUSA
| | - Mauricio H Serpa
- Laboratory of Psychiatric Neuroimaging (LIM‐21), Departamento e Instituto de Psiquiatria, Hospital das Clinicas HCFMUSP, Faculdade de MedicinaUniversidade de São PauloSão PauloBrazil
| | - Kang Sim
- West Region, Institute of Mental HealthSingaporeSingapore
- Yong Loo Lin School of MedicineNational University of SingaporeSingapore
| | - Andrew Simmons
- Department of Neuroimaging, Institute of PsychiatryPsychology and Neurology, King's College LondonLondonUK
| | - Jordan W Smoller
- Department of PsychiatryMassachusetts General HospitalBostonMassachusettsUSA
- Psychiatric and Neurodevelopmental Genetics Unit, Center for Genomic MedicineMassachusetts General HospitalBostonMassachusettsUSA
| | - Iris E Sommer
- Department of Biomedical Sciences of Cells and Systems, Rijksuniversiteit GroningenUniversity Medical Center GroningenGroningenThe Netherlands
| | - Carles Soriano‐Mas
- Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM)MadridSpain
- Department of Psychiatry, Bellvitge University HospitalBellvitge Biomedical Research Institute‐IDIBELLBarcelonaSpain
- Department of Psychobiology and Methodology in Health SciencesUniversitat Autònoma de BarcelonaBarcelonaSpain
| | - Dan J Stein
- SAMRC Unit on Risk & Resilience in Mental Disorders, Dept of Psychiatry & Neuroscience InstituteUniversity of Cape TownCape TownWestern CapeSouth Africa
| | - Lachlan T Strike
- Queensland Brain InstituteUniversity of QueenslandBrisbaneQueenslandAustralia
| | - Philip R Szeszko
- Department of PsychiatryIcahn School of Medicine at Mount SinaiNew YorkNew YorkUSA
- Mental Illness Research, Education and Clinical Center (MIRECC)James J. Peters VA Medical CenterNew YorkNew YorkUSA
| | - Henk S Temmingh
- Department of Psychiatry and Mental HealthUniversity of Cape TownCape TownWestern CapeSouth Africa
| | - Sophia I Thomopoulos
- Imaging Genetics Center, Mark and Mary Stevens Neuroimaging and Informatics Institute, Keck School of MedicineUniversity of Southern CaliforniaLos AngelesCaliforniaUSA
| | - Alexander S Tomyshev
- Laboratory of Neuroimaging and Multimodal AnalysisMental Health Research CenterMoscowRussia
| | - Julian N Trollor
- Centre for Healthy Brain Ageing, School of PsychiatryUniversity of New South WalesSydneyNew South WalesAustralia
| | - Anne Uhlmann
- Department of Psychiatry and Mental HealthUniversity of Cape TownCape TownWestern CapeSouth Africa
- Department of Child and Adolescent Psychiatry and PsychotherapyFaculty of Medicine Carl Gustav Carus of TU DresdenDresdenGermany
| | - Ilya M Veer
- Department of Psychiatry and Psychotherapy CCM, Charité ‐ Universitätsmedizin Berlin, corporate member of Freie Universität BerlinHumboldt‐Universität zu Berlin, and Berlin Institute of HealthBerlinGermany
| | - Dick J Veltman
- Department of Psychiatry & Amsterdam NeuroscienceAmsterdam UMC, location VUMCAmsterdamThe Netherlands
| | - Aristotle Voineskos
- Campbell Family Mental Health Institute, Centre for Addiction and Mental Health, Department of PsychiatryUniversity of TorontoTorontoCanada
| | - Henry Völzke
- Institute for Community MedicineUniversity Medicine GreifswaldGreifswaldGermany
- DZHK (German Centre for Cardiovascular Research), partner site GreifswaldGreifswaldGermany
- DZD (German Center for Diabetes Research), partner site GreifswaldGreifswaldGermany
| | - Henrik Walter
- Department of Psychiatry and Psychotherapy CCM, Charité ‐ Universitätsmedizin Berlin, corporate member of Freie Universität BerlinHumboldt‐Universität zu Berlin, and Berlin Institute of HealthBerlinGermany
| | - Lei Wang
- Department of Psychiatry and Behavioral SciencesNorthwestern University Feinberg School of MedicineChicagoIllinoisUSA
| | - Yang Wang
- Department of RadiologyMedical College of WisconsinMilwaukeeWisconsinUSA
| | - Bernd Weber
- Institute for Experimental Epileptology and Cognition ResearchUniversity Hospital BonnBonnGermany
| | - Wei Wen
- Centre for Healthy Brain Ageing, School of PsychiatryUniversity of New South WalesSydneyNew South WalesAustralia
| | - John D West
- Department of Radiology and Imaging SciencesIndiana University School of MedicineIndianapolisIndianaUSA
| | - Lars T Westlye
- Norwegian Centre for Mental Disorders Research (NORMENT), Division of Mental Health and Addiction, Institute of Clinical MedicineUniversity of OsloOsloNorway
- Norwegian Centre for Mental Disorders Research (NORMENT), Division of Mental Health and AddictionOslo University HospitalOsloNorway
- Department of PsychologyUniversity of OsloOsloNorway
| | - Heather C Whalley
- Division of PsychiatryUniversity of EdinburghEdinburghUK
- Division of PsychiatryRoyal Edinburgh HospitalEdinburghUK
| | | | - Katharina Wittfeld
- Department of Psychiatry and PsychotherapyUniversity Medicine GreifswaldGreifswaldGermany
- German Center for Neurodegenerative Diseases (DZNE)Site Rostock/GreifswaldGreifswaldGermany
| | - Daniel H Wolf
- Department of PsychiatryUniversity of PennsylvaniaPhiladelphiaPennsylvaniaUSA
| | - Margaret J Wright
- Queensland Brain InstituteUniversity of QueenslandBrisbaneQueenslandAustralia
- Centre for Advanced ImagingUniversity of QueenslandBrisbaneQueenslandAustralia
| | - Yuliya N Yoncheva
- Department of Child and Adolescent Psychiatry, NYU Child Study CenterHassenfeld Children's Hospital at NYU LangoneNew YorkNew YorkUSA
| | - Marcus V Zanetti
- Laboratory of Psychiatric Neuroimaging (LIM‐21), Departamento e Instituto de Psiquiatria, Hospital das Clinicas HCFMUSP, Faculdade de MedicinaUniversidade de São PauloSão PauloBrazil
- Instituto de Ensino e PesquisaHospital Sírio‐LibanêsSão PauloBrazil
| | - Georg C Ziegler
- Division of Molecular Psychiatry, Center of Mental HealthUniversity of WürzburgWürzburgGermany
| | - Greig I de Zubicaray
- Faculty of Health, Institute of Health and Biomedical InnovationQueensland University of Technology (QUT)BrisbaneQueenslandAustralia
| | - Paul M Thompson
- Imaging Genetics Center, Mark and Mary Stevens Neuroimaging and Informatics Institute, Keck School of MedicineUniversity of Southern CaliforniaLos AngelesCaliforniaUSA
| | - Eveline A Crone
- Institute of PsychologyLeiden UniversityLeidenThe Netherlands
- Leiden Institute for Brain and CognitionLeidenThe Netherlands
- Department of Psychology, Education and Child Studies (DPECS), Erasmus School of Social and Behavioral SciencesErasmus University RotterdamThe Netherlands
| | - Sophia Frangou
- Department of PsychiatryIcahn School of Medicine at Mount SinaiNew YorkNew YorkUSA
- Centre for Brain HealthUniversity of British ColumbiaVancouverBritish ColumbiaCanada
| | - Christian K Tamnes
- Norwegian Centre for Mental Disorders Research (NORMENT), Division of Mental Health and Addiction, Institute of Clinical MedicineUniversity of OsloOsloNorway
- Department of Psychiatric ResearchDiakonhjemmet HospitalOsloNorway
- PROMENTA Research Center, Department of PsychologyUniversity of OsloOsloNorway
| |
Collapse
|
38
|
Grober E, Papp KV, Rentz DM, Sperling RA, Johnson KA, Amariglio RE, Schultz A, Lipton RB, Ezzati A. Neuroimaging correlates of Stages of Objective Memory Impairment (SOMI) system. Alzheimers Dement (Amst) 2021; 13:e12224. [PMID: 35005192 PMCID: PMC8719429 DOI: 10.1002/dad2.12224] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 02/22/2021] [Revised: 06/11/2021] [Accepted: 06/11/2021] [Indexed: 06/14/2023]
Abstract
INTRODUCTION To assess the relationship between memory performance defined by the Stages of Objective Memory Impairment (SOMI) system and the Alzheimer's disease (AD) ATN (amyloid beta [A], pathologic tau [T], and neurodegeneration [N]) biomarker system. METHODS We used data from the Harvard Aging Brain Study cohort to estimate the level of ATN biomarkers: amyloid beta (C-Pittsburgh compound B-positron emission tomography [PET]), tau (F-18-flortaucipir [FTP] PET), and neurodegeneration (magnetic resonance imaging volumetrics). We assessed the cross-sectional relationship of SOMI classification with global amyloid levels, entorhinal and inferior temporal tau deposition, and hippocampal atrophy. RESULTS Participants with both memory storage and retrieval deficits (SOMI-3, -4) had smaller hippocampal volumes and higher entorhinal and inferior temporal tau burden than participants with no memory impairment (SOMI-0) or mild retrieval difficulty (SOMI-1). Amyloid burden did not differ among SOMI stages. DISCUSSION This pilot supports the close relationship between tau pathology and memory impairment across the AD continuum. SOMI may be useful to determine eligibility for randomized controlled trials prior to the assessment of biomarker status.
Collapse
Affiliation(s)
- Ellen Grober
- Department of NeurologyAlbert Einstein College of Medicine and Montefiore Medical CenterBronxNew YorkUSA
| | - Kathryn V. Papp
- Harvard Aging Brain StudyDepartment of NeurologyMassachusetts General HospitalHarvard Medical SchoolBostonMassachusettsUSA
- Center for Alzheimer Research and TreatmentDepartment of NeurologyBrigham and Women's HospitalBostonMassachusettsUSA
| | - Dorene M. Rentz
- Harvard Aging Brain StudyDepartment of NeurologyMassachusetts General HospitalHarvard Medical SchoolBostonMassachusettsUSA
- Center for Alzheimer Research and TreatmentDepartment of NeurologyBrigham and Women's HospitalBostonMassachusettsUSA
| | - Reisa A. Sperling
- Harvard Aging Brain StudyDepartment of NeurologyMassachusetts General HospitalHarvard Medical SchoolBostonMassachusettsUSA
- Center for Alzheimer Research and TreatmentDepartment of NeurologyBrigham and Women's HospitalBostonMassachusettsUSA
| | - Keith A. Johnson
- Harvard Aging Brain StudyDepartment of NeurologyMassachusetts General HospitalHarvard Medical SchoolBostonMassachusettsUSA
- Center for Alzheimer Research and TreatmentDepartment of NeurologyBrigham and Women's HospitalBostonMassachusettsUSA
| | - Rebecca E. Amariglio
- Harvard Aging Brain StudyDepartment of NeurologyMassachusetts General HospitalHarvard Medical SchoolBostonMassachusettsUSA
- Center for Alzheimer Research and TreatmentDepartment of NeurologyBrigham and Women's HospitalBostonMassachusettsUSA
| | - Aaron Schultz
- Harvard Aging Brain StudyDepartment of NeurologyMassachusetts General HospitalHarvard Medical SchoolBostonMassachusettsUSA
| | - Richard B. Lipton
- Department of NeurologyAlbert Einstein College of Medicine and Montefiore Medical CenterBronxNew YorkUSA
| | - Ali Ezzati
- Department of NeurologyAlbert Einstein College of Medicine and Montefiore Medical CenterBronxNew YorkUSA
| |
Collapse
|
39
|
Cummings JL, Ismail Z, Dickerson BC, Ballard C, Grossberg G, McEvoy B, Foff E, Atri A. Development and assessment of a brief screening tool for psychosis in dementia. Alzheimers Dement (Amst) 2021; 13:e12254. [PMID: 34934801 PMCID: PMC8650749 DOI: 10.1002/dad2.12254] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 07/08/2021] [Revised: 09/03/2021] [Accepted: 09/15/2021] [Indexed: 11/06/2022]
Abstract
INTRODUCTION Hallucinations and delusions (H+D) are common in dementia, but screening for these symptoms-especially in busy clinical practices-is challenging. METHODS Six subject matter experts developed the DRP3™ screen, a novel valid tool to detect H+D in dementia, assessed its content validity through alignment with DRP reference assessments (Scale for the Assessment of Positive Symptoms-Hallucinations + Delusions, Neuropsychiatric Inventory-Questionnaire, International Psychogeriatric Association Criteria), and retrospectively investigated its ability to detect H+D in HARMONY trial (NCT03325556) enrollees. RESULTS All items from three reference assessments demonstrated significant agreement with the DRP3 screen among raters (P < .0001). Retrospectively applying the DRP3 screen to HARMONY identified all (N = 392) trial enrollees. DISCUSSION The DRP3 screen, comprising three yes/no questions, is a content-valid tool for detecting H+D in dementia that aligned with current reference assessments and successfully identified trial participants when retrospectively applied to a completed trial. Within busy practice constraints, the DRP3 screen provides a brief tool for sensitive detection of H+D in patients with dementia.
Collapse
Affiliation(s)
- Jeffrey L. Cummings
- Chambers‐Grundy Center for Transformative NeuroscienceDepartment of Brain HealthSchool of Integrated Health SciencesUniversity of Nevada Las VegasLas VegasNevadaUSA
| | - Zahinoor Ismail
- Hotchkiss Brain InstituteUniversity of CalgaryO'Brien Institute for Public HealthUniversity of CalgaryCalgaryAlbertaCanada
| | | | | | | | | | - Erin Foff
- Acadia Pharmaceuticals Inc.San DiegoCaliforniaUSA
| | - Alireza Atri
- Banner Sun Health Research InstituteBanner HealthSun CityArizonaUSA
- Harvard Medical SchoolBrigham and Women's HospitalBostonMassachusettsUSA
| |
Collapse
|
40
|
Walker KA, Silverstein N, Zhou Y, Hughes TM, Jack CR, Knopman DS, Sharrett AR, Wong DF, Mosley TH, Gottesman RF. Brain White Matter Structure and Amyloid Deposition in Black and White Older Adults: The ARIC-PET Study. J Am Heart Assoc 2021; 10:e022087. [PMID: 34431373 PMCID: PMC8649279 DOI: 10.1161/jaha.121.022087] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/15/2021] [Accepted: 07/26/2021] [Indexed: 12/30/2022]
Abstract
Background White matter abnormalities are a common feature of aging and Alzheimer disease, and tend to be more severe among Black individuals. However, the extent to which white matter abnormalities relate to amyloid deposition, a marker of Alzheimer pathology, remains unclear. This cross-sectional study examined the association of white matter abnormalities with cortical amyloid in a community sample of older adults without dementia and examined the moderating effect of race. Methods and Results Participants from the ARIC-PET (Atherosclerosis Risk in Communities-Positron Emission Tomography) study underwent brain magnetic resonance imaging, which quantified white matter hyperintensity volume and microstructural integrity using diffusion tensor imaging. Participants received florbetapir positron emission tomography imaging to measure brain amyloid. Associations between measures of white matter structure and elevated amyloid status were examined using multivariable logistic regression. Among 322 participants (43% Black), each SD increase in white matter hyperintensity volume was associated with a greater odds of elevated amyloid (odds ratio [OR], 1.37; 95% CI, 1.03-1.83) after adjusting for demographic and cardiovascular risk factors. In race-stratified analyses, a greater white matter hyperintensity volume was more strongly associated with elevated amyloid among Black participants (OR, 2.00; 95% CI, 1.15-3.50), compared with White participants (OR, 1.29; 95% CI, 0.89-1.89). However, the race interaction was not statistically significant (P interaction=0.09). We found no association between white matter microstructure and elevated amyloid. Conclusions The results suggest a modest positive relationship between white matter hyperintensity and elevated amyloid in older adults without dementia. Although the results indicate that this association is nonsignificantly stronger among Black participants, these findings will need to be confirmed or refuted using larger multiracial cohorts.
Collapse
Affiliation(s)
- Keenan A. Walker
- Laboratory of Behavioral NeuroscienceNational Institute on AgingIntramural Research ProgramBaltimoreMD
| | - Noah Silverstein
- Department of MedicineSUNY Downstate Health Sciences UniversityBrooklynNY
| | - Yun Zhou
- Mallinckrodt Institute of RadiologyWashington University School of Medicine in St. LouisMO
- United TechnologiesShanghaiChina
| | - Timothy M. Hughes
- Department of Internal MedicineSection on Gerontology and Geriatrics MedicineWake Forest School of MedicineWinston‐SalemNC
| | | | | | - A. Richey Sharrett
- Department of EpidemiologyJohns Hopkins Bloomberg School of Public HealthBaltimoreMD
| | - Dean F. Wong
- Mallinckrodt Institute of RadiologyWashington University School of Medicine in St. LouisMO
| | - Thomas H. Mosley
- Department of MedicineDivision of GeriatricsUniversity of Mississippi Medical CenterJacksonMS
| | - Rebecca F. Gottesman
- Stroke BranchNational Institute of Neurological Disorders and Stroke Intramural Research ProgramNIHBethesdaMD
| |
Collapse
|
41
|
Andresen NS, Sharon JD, Nieman CL, Seal SM, Ward BK. Predictive value of the Eustachian Tube Dysfunction Questionnaire-7 for identifying obstructive Eustachian tube dysfunction: A systematic review. Laryngoscope Investig Otolaryngol 2021; 6:844-851. [PMID: 34401511 PMCID: PMC8356874 DOI: 10.1002/lio2.606] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/09/2021] [Revised: 05/26/2021] [Accepted: 06/10/2021] [Indexed: 01/01/2023] Open
Abstract
OBJECTIVE To perform a systematic review to determine if a total score of ≥14.5 (mean score ≥ 2.1) on the ETDQ-7 accurately identifies patients with obstructive Eustachian tube dysfunction (OETD) on impedance tympanometry (peak compliance <0.2 mL or middle ear pressure of -100 daPa) or other objective measures of OETD. METHODS A systematic review without a meta-analysis was performed of studies in four electronic databases (Pubmed, Embase, Web of Science, and Scopus) that used the ETDQ-7 and at least one objective measure of OETD. RESULTS Six-hundred and fifty-two studies were identified in the initial literature search. Abstracts from 337 studies were screened, followed by full-text review of 61 studies, and qualitative synthesis of 12 studies. Tympanometry was used as an objective measure in ten studies. Eight of the 12 included studies had patient cohort selection bias. Eight studies administered the ETDQ-7 in cohorts of patients with or without OETD, already confirmed on tympanometry, and found a sensitivity of 91%-100% and specificity of 67%-100%. Four studies administered the ETDQ-7 to patients who had not previously undergone objective testing and found a sensitivity of 49%-80% and specificity of 24%-78%. CONCLUSIONS The ETDQ-7 is an important patient-reported outcome measure. However, based upon existing literature, the ETDQ-7 appears limited as a diagnostic tool for OETD or as an objective measure of Eustachian tube function.
Collapse
Affiliation(s)
- Nicholas S. Andresen
- Department of Otolaryngology—Head and Neck SurgeryJohns Hopkins University School of MedicineBaltimoreMarylandUSA
| | - Jeffrey D. Sharon
- Department of Otolaryngology—Head and Neck SurgeryUniversity of California—San FranciscoSan FranciscoCaliforniaUSA
| | - Carrie L. Nieman
- Department of Otolaryngology—Head and Neck SurgeryJohns Hopkins University School of MedicineBaltimoreMarylandUSA
- Cochlear Center for Hearing and Public HealthJohns Hopkins Bloomberg School of Public HealthBaltimoreMarylandUSA
| | - Stella M. Seal
- Welch Medical LibraryJohns Hopkins University School of MedicineBaltimoreMarylandUSA
| | - Bryan K. Ward
- Department of Otolaryngology—Head and Neck SurgeryJohns Hopkins University School of MedicineBaltimoreMarylandUSA
| |
Collapse
|
42
|
Carlson ML, Toueg TN, Khalighi MM, Castillo J, Shen B, Azevedo EC, DiGiacomo P, Mouchawar N, Chau G, Zaharchuk G, James ML, Mormino EC, Zeineh MM. Hippocampal subfield imaging and fractional anisotropy show parallel changes in Alzheimer's disease tau progression using simultaneous tau-PET/MRI at 3T. Alzheimers Dement (Amst) 2021; 13:e12218. [PMID: 34337132 PMCID: PMC8319659 DOI: 10.1002/dad2.12218] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 03/11/2021] [Revised: 06/01/2021] [Accepted: 06/04/2021] [Indexed: 01/03/2023]
Abstract
INTRODUCTION Alzheimer's disease (AD) is the most common form of dementia, characterized primarily by abnormal aggregation of two proteins, tau and amyloid beta. We assessed tau pathology and white matter connectivity changes in subfields of the hippocampus simultaneously in vivo in AD. METHODS Twenty-four subjects were scanned using simultaneous time-of-flight 18F-PI-2620 tau positron emission tomography/3-Tesla magnetic resonance imaging and automated segmentation. RESULTS We observed extensive tau elevation in the entorhinal/perirhinal regions, intermediate tau elevation in cornu ammonis 1/subiculum, and an absence of tau elevation in the dentate gyrus, relative to controls. Diffusion tensor imaging showed parahippocampal gyral fractional anisotropy was lower in AD and mild cognitive impairment compared to controls and strongly correlated with early tau accumulation in the entorhinal and perirhinal cortices. DISCUSSION This study demonstrates the potential for quantifiable patterns of 18F-PI2620 binding in hippocampus subfields, accompanied by diffusion and volume metrics, to be valuable markers of AD.
Collapse
Affiliation(s)
| | - Tyler N. Toueg
- Department of NeurologyStanford UniversityStanfordCaliforniaUSA
| | | | - Jessa Castillo
- Department of RadiologyStanford UniversityStanfordCaliforniaUSA
| | - Bin Shen
- Department of RadiologyStanford UniversityStanfordCaliforniaUSA
| | | | - Phillip DiGiacomo
- Department of BioengineeringStanford UniversityStanfordCaliforniaUSA
| | | | - Gustavo Chau
- Department of BioengineeringStanford UniversityStanfordCaliforniaUSA
| | - Greg Zaharchuk
- Department of RadiologyStanford UniversityStanfordCaliforniaUSA
| | - Michelle L. James
- Department of NeurologyStanford UniversityStanfordCaliforniaUSA
- Department of RadiologyStanford UniversityStanfordCaliforniaUSA
| | | | | |
Collapse
|
43
|
Bucholc M, McClean PL, Bauermeister S, Todd S, Ding X, Ye Q, Wang D, Huang W, Maguire LP. Association of the use of hearing aids with the conversion from mild cognitive impairment to dementia and progression of dementia: A longitudinal retrospective study. Alzheimers Dement (N Y) 2021; 7:e12122. [PMID: 33614893 PMCID: PMC7882528 DOI: 10.1002/trc2.12122] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 06/28/2020] [Revised: 09/12/2020] [Accepted: 11/11/2020] [Indexed: 12/26/2022]
Abstract
INTRODUCTION Hearing aid usage has been linked to improvements in cognition, communication, and socialization, but the extent to which it can affect the incidence and progression of dementia is unknown. Such research is vital given the high prevalence of dementia and hearing impairment in older adults, and the fact that both conditions often coexist. In this study, we examined for the first time the effect of the use of hearing aids on the conversion from mild cognitive impairment (MCI) to dementia and progression of dementia. METHODS We used a large referral-based cohort of 2114 hearing-impaired patients obtained from the National Alzheimer's Coordinating Center. Survival analyses using multivariable Cox proportional hazards regression model and weighted Cox regression model with censored data were performed to assess the effect of hearing aid use on the risk of conversion from MCI to dementia and risk of death in hearing-impaired participants. Disease progression was assessed with Clinical Dementia Rating Sum of Boxes (CDR-SB) scores. Three types of sensitivity analyses were performed to validate the robustness of the results. RESULTS MCI participants that used hearing aids were at significantly lower risk of developing all-cause dementia compared to those not using hearing aids (hazard ratio [HR] 0.73, 95% confidence interval [CI], 0.61 to 0.89; false discovery rate [FDR] P = 0.004). The mean annual rate of change (standard deviation) in CDR-SB scores for hearing aid users with MCI was 1.3 (1.45) points and significantly lower than for individuals not wearing hearing aids with a 1.7 (1.95) point increase in CDR-SB per year (P = 0.02). No association between hearing aid use and risk of death was observed. Our findings were robust subject to sensitivity analyses. DISCUSSION Among hearing-impaired adults, hearing aid use was independently associated with reduced dementia risk. The causality between hearing aid use and incident dementia should be further tested.
Collapse
Affiliation(s)
- Magda Bucholc
- Cognitive Analytics Research LabSchool of Computing, Engineering & Intelligent SystemsUlster UniversityDerryUK
| | - Paula L. McClean
- Northern Ireland Centre for Stratified MedicineBiomedical Sciences Research InstituteClinical Translational Research and Innovation Centre (C‐TRIC)Ulster UniversityDerryUK
| | | | - Stephen Todd
- Altnagelvin Area HospitalWestern Health and Social Care TrustDerryUK
| | - Xuemei Ding
- Cognitive Analytics Research LabSchool of Computing, Engineering & Intelligent SystemsUlster UniversityDerryUK
- Fujian Provincial Engineering Technology Research Centre for Public Service Big Data Mining and ApplicationCollege of Mathematics and InformaticsFujian Normal UniversityFuzhouFujianChina
| | - Qinyong Ye
- Department of NeurologyFujian Medical University Union HospitalFuzhouFujianChina
| | - Desheng Wang
- Department of OtolaryngologyFujian Medical University Union HospitalFuzhouFujianChina
| | - Wei Huang
- Department of OtolaryngologyFujian Medical University Union HospitalFuzhouFujianChina
| | - Liam P. Maguire
- Cognitive Analytics Research LabSchool of Computing, Engineering & Intelligent SystemsUlster UniversityDerryUK
| |
Collapse
|